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In the female, vascular endothelial growth factor A (VEGFA) isoforms regulate
follicle development and affect the initial primordial follicle pool. In male rodent testes,
they are involved in the development of vasculature and seminiferous cords. The
objective of the current study was to evaluate effects of Sertoli and Granulosa cellspecific production of VEGFA isoforms on vascular development and gonadal
morphogenesis. We used a DMRT1-cre crossed to a floxed VEGFA mouse to determine
potential phenotypes in male Sertoli-cell (VEGFA-DSertG) and female Granulosa-cell
(VEGFA-DGranG) specific knockouts. In females, we found smaller ovarian weight,
fewer corpus luteums (CLs) with some abnormal CL morphology, and 55% reduction in
estrogen in the VEGFA-DGranG compared to controls. The number of days mated until
parturition was 12 days longer in VEGFA-DGranG X VEGFA-DSertG pairs versus
control females mating with control males. In males, the weight of body, testes and
epididymides in VEGFA-DSertG mice were significantly reduced than those from the
controls. The morphology of epididymis and prostate appeared to be different with less
tubules and branching, respectively compared to controls. Serum testosterone levels in
VEGFA-DSertG tended to be higher than those in controls. Bcl-2 mRNA and Bcl-2/Bax

in VEGFA-DSertG testis tended to be higher than that in controls. Sin3a mRNA within
testis was higher in those three VEGFA-DSertG males with high serum testosterone
concentration than controls. Therefore, we conclude that lack of VEGFA in Granulosa
and Sertoli cells alters reproductive organ morphogenesis, reduces gonadal and male
accessory gland organ weights, alters steroidogenesis and creates sub-fertility in mice.
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Chapter 1
Literature Review
Introduction
Over the past decades, fertility has sharply declined and the proportion of couples
who need infertility treatment has increased tremendously (Leridon et al., 2008). About
one-half of infertility cases are due to male factors such as cryptorchidism,
oligozoospermia and the other one-half are attributed to female such as uterine and pelvic
abnormalities, secondary infertility, polycystic ovarian syndrome. Currently increased
human infertility suggests that significant reproductive health problems exist
(Skakkebaek et al., 2005).
VEGFA is also present during testis morphogenesis and expressed by Sertoli cells
which play an important role in the testis formation and function. The incidence of male
reproductive disorders including impaired spermatogenesis, undescended testis,
hypospadia and testicular cancer has been increasing during recent decades. These
reproductive disorders could be called testicular dysgenesis syndrome (TDS) (Funke et
al., 2010). One potential cause of TDS may be due to disruptions in embryonic gonadal
development. Our laboratory has demonstrated that inhibition of VEGFA angiogenic
isoforms arrested both testis cord formation and vascular development in mice (Bott et al.,
2006). Excess of VEGFA angiogenic isoform resulted in less organized and poorer
seminiferous cords in rat testis (Baltes-Breitwisch et al., 2010). VEGFA signal
transduction inhibitors reduced the endothelial cell migration during testis formation in
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mice (Bott et al., 2010). Furthermore, overexpression of VEGFA in transgenic mice
results in infertility (Korpelainen et al. 1998).
Vascular Endothelial Growth Factor A (VEGFA) is paracrine growth factor
responsible for blood vessel development as well as endothelial cell migration. VEGFA
expression and production within the ovary are critical for normal reproductive function.
In the female, VEGFA plays an important role in the cyclic growth of ovarian follicles
and in the development and maintenance of corpus luteum (CL) by mediating ovarian
angiogenesis. Defects in angiogenesis may cause some disorders such as anovulation,
pregnancy loss, ovarian hyperstimulation syndrome, and ovarian neoplasms (Geva and
Jaffe, 2000). Previous studies in our laboratory demonstrated that VEGFA is involved in
primordial follicle activation, maturation and survival (McFee et al., 2009; Artac et al.,
2009).
The objective of my research is to evaluate the effect of granulosa and Sertoli cellspecific production of VEGFA isoforms on vascular development and gonadal
morphogenesis.
Testis morphogenesis
There are at least five morphological stages of testis development: (1) development
of a genital ridge, (2) formation of an indifferent or bipotential gonad, (3) sex
determination, (4) induction of testicular cords in the testis, and (5) development of a
functional testis (Fig. 1) (Cupp and Skinner 2005).
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Development of a genital ridge
Development of a genital ridge occurs in both male and female. Formation of the
genital ridge and urogenital system from the intermediate mesoderm starts at 9-9.5 days
post coitus (dpc) in the mouse. In male, Woffian duct formation is driven by lateral
mesoderm and develops from the mesonephric duct (Grobstein, 1953). Several genes
such as Lhx1 (LIM homeobox 1), Wilms’ tumor 1 (Wt1) and Emx2 are expressed in the
urogenital ridge by 9.5 dpc in the mouse and contribute to the development of the
indifferent gonads (Shawlot et al., 1995; Kreidberg et al., 1993; Miyamoto et al., 1997).
At approximately 10.5 dpc, the gonad forms as an outgrowth of the genital ridge in both
male and female (Brennan et al., 2002). Then, the coelomic epithelium of the urogenital
ridges will develop to the indifferent gonads (Cui et al., 2004).
Formation of an indifferent gonad
The second stage of testis morphogenesis is the development of indifferent gonad. In
the mouse, the indifferent gonad becomes visible at 10 dpc but still cannot be identified
as a testis or ovary (Swain and Lovell-Badge, 1999). The indifferent gonad can
differentiate to testis or ovary depending on the transcription factors expressed in the
differentiating somatic cells of the coelomic epithelium (Cupp and Skinner, 2005). In XY
gonads, primordial germ cells (PGCs) migrate long distances from the yolk sac to the
prospective gonads (Aman and Piotrowski, 2010). The migration of PGCs in the mouse is
induced at the interface between extraembryonic and embryonic tissues. Bone
morphogenetic protein (BMP) 4 and 8 signaling from the extraembryonic ectoderm is
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required for this induction (Kunwar et al., 2006). The migration of PGCs is from the gut
to somatic gonadal mesoderm to colonize the gonads (Bendel-Stenzel et al. 1998,
Molyneaux and Wylie, 2004). Kit ligand (KL) plays a critical role in regulation of PGC
survival by preventing PGC apoptosis. Kit Ligand also promotes PGC migration due to
its function as an adhesion factor (De and Pesce, 1994; De et al., 2009).
Sex Determination
The third stage of testis development is sex determination. Testis determination is
controlled by Sry (Sex-determining Region Y). Sry gene is male sex-determining gene on
the Y chromosome (Martineau et al., 1997). Expression of Sry transgenic in XX mice
results in the initiation of testis cord formation (Koopman et al., 1991; Eicher et al.,
1995). In the mouse, the Sry gene is expressed at 10.5 dpc and ceases after 12.5 dpc. Sry
stimulates expression of genes such as Sry box9 (Sox9) which cause the differentiation of
the Sertoli cell from coelomic epithelial cells (Karl and Capel, 1998). The Sertoli cell is
the first cell to differentiate in the testis (Magre and Jost 1991). After differentiation,
Sertoli cells move into the gonad and aggregate with primordial germ cells and start
proliferate at 11.25 dpc in the mouse. Proliferation of Sertoli cells increases the size of
testis and is determined by the expression of Sry (Schmahl et al. 2000; Schmahl and
Capel 2003).
Induction of testicular cords in the testis
The fourth stage is induction of testicular morphology and seminiferous cord
formation. Testicular cord formation is an important event in establishing the adult testis
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morphology. In the mouse after Sertoli cell differentiation, formation of testicular cords
and sex-specific vascularization occur around 11.5 -12 dpc and are complete by 12.5 dpc
(Martineau et al., 1997). First step in cord formation is aggregation of Sertoli cells with
PGCs. The second step is the migration of mesonephric cells from the adjacent
mesonephros to the differentiating testis (Cupp and Skinner 2005). Testis development is
initiated by Sertoli cell differentiation and Sry expression. Testis failed to develop welldifferentiated testis cords when mesonephros was removed at 11.5 dpc (Buehr et al.,
1993). Migration of mesonephric cells is required for seminiferous cord formation
(Merchant-Larios et al., 1993). It has been demonstrated that some paracrine growth
factors such as Hepatocyte growth factor (HGF), Fibroblast growth factor 9 (Fgf9),
neurotropin-3 (NT3), VEGF and Platelet-derived growth factors (PDGFs) are involved in
mesonephric cell migration and cord formation (Ricci et al. 1999; Colvin et al. 2001;
Cupp et al. 2003; Bott et al., 2006). In addition to surrounding the Sertoli-primordial
germ cell aggregates to form testis cords, the migrating mesonephric cells may also
initiate the formation of vasculature in the testis (Bott et al., 2008). Formation of
testicular cords and sex-specific vasculature are the key morphological markers to
distinguish a testis from an ovary.
Development of a functional testis
The last step in testis morphogenesis is development of a functional testis. After
seminiferous cord is formed, the other cells within the testis begin to differentiate. Sertoli
cells produce the factors to initiate interstitial, peritubular, and Leydig cell differentiation
(Cupp and Skinner, 2005). The peritubular cell surrounds and forms the exterior wall of
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the seminiferous tubule. The peritubular and the Sertoli cells form the basement
membrane surrounding the seminiferous tubule and their interactions are critical for germ
cell development. The interstitial space outside the seminiferous tubules has the Leydig
cells which are responsible for testicular steroid production (Skinner and Anway et al.,
2005). Estrogens and androgens have effects on testis growth, development of cell
populations and differentiation of male reproductive tracts (Cupp and Skinner, 2005).
Spermatogenesis
Spermatogenesis is the process of sperm formation and maturation. It occurs in the
seminiferous epithelium of the testis and is characterized by continuous germ cell
maturation towards the center of the seminiferous tubules. During this time male germ
cells undergo both mitotic and then meiotic divisions (Ruwanpura et al., 2010). Specially,
there is mitotic proliferation of spermatogonia, meiotic division of spermatocytes,
differentiation of spermatids and final release of spermatozoa into the tubule lumen
(Tripathi et al., 2009). Gonocytes in the postnatal testis arise from PGCs and then
develop to spermatogonial stem cells (SSCs). The foundation of spermatogenesis is SSC
(Phillips et al., 2010). Spermatogenic lineage development is referred to as the
spermatogenic cycle (Clermont, 1972).
Spermatogonia are at the basement membrane of the seminiferous tubules. They are
the primitive diploid germ cells (Phillips et al., 2010). Undifferentiated type A
spermatogonia differ in the topographical arrangement on the seminiferous tubule
basement membrane and can be subdivided into Asingle (As), Apaired (Apr) and Aaligned (Aal)
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spermatogonia (Huckins, 1971). Differentiating spermatogonia (A1, A2, A3, A4 and B)
are found at specific stages of the seminiferous epithelium (Oakberg, 1971). Type B
spermatogonia develop to primary spermatocytes that then progress to meiosis. Two
meiotic divisions lead to the formation of secondary spermatocytes and haploid
spermatids respectively. Spermatids mature into spermatozoa which will be released from
the seminiferous epithelium (Phillips et al., 2010). During normal spermatogenesis,
apoptosis regulates the ratio of Sertoli cells to germ cell number. Apoptosis induces
programmed cell death to eliminate the germ cells which fail to replicate their DNA
accurately during cell division (Ruwanpura et al., 2010).
Hormonal regulation of spermatogenesis
The role of FSH in spermatogenesis
The size of the Sertoli cell population is set in early postnatal life and it is a major
determinant of sperm output in the adult animal (Ruwanpura et al., 2010). FSH increases
the proliferation of Sertoli cells (Sharpe et al., 2003); regulates the spermatogonial
population in rodents (McLachlan et al. 2002) and has been demonstrated to be involved
in spermatogonial survival (Beardsley & O’Donnell 2003; Ruwanpura et al. 2008a). An
in vivo study demonstrated that FSH contributes to the proliferation of undifferentiated
type A spermatogonia in immature testis cultures (Boitani et al., 1993). If FSH is
suppressed then there is an increase in spermatogonial apoptosis in immature and adult
rats (Ruwanpura et al. 2008a, b, 2010). Besides its role in regulation of spermatogonia
population, FSH also plays roles in meiosis and spermiogenesis. Vihko et al. reported
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that FSH is critical for the meiosis in the first wave of rat spermatogenesis (Vihko et al.,
1991). Hypogonadal (hpg) mice expressing transgenic FSH showed that FSH supports
spermatogonial proliferation and the stimulation of meiotic and post-meiotic germ cell
development (Haywood et al. 2003).
The role of testosterone in spermatogenesis
In immature testes, testosterone is essential for gonadal maturation and testicular
differentiation (Ruwanpura et al., 2010). Somatic Sertoli cells transduce signals from
testosterone into the production of factors that are necessary for germ cells when they
become spermatozoa (Walker and Cheng 2005). Only Leydig cells, peritubular cells and
Sertoli cells express androgen receptor (AR). No AR is expressed in germ cells of the
mature testis (Walker and Cheng 2005). It is demonstrated that testosterone is able to
suppress Sertoli cell proliferative activity in vitro (Buzzard et al., 2003). Without
testosterone, progressive germ cell degeneration begins during stage VII of the
spermatogenic cycle (Walker and Cheng 2005). In the absence of androgen replacement,
spermatogenesis is arrested during meiosis in Hpg male mice which lack both FSH and
LH because of an inactivated mutation at the GnRH locus. Testosterone treatment also
confers a qualitative recovery of spermatogenesis in Hpg mice (Holdcraft and Braun
2004). AR Sertoli cell knockout mice appeared arrested at late spermatocytes, indicating
that the completion of meiosis and spermatogenesis is in need of androgen in the first
spermatogenic wave (Chang et al. 2004; De Gendt et al. 2004). Testosterone not only
plays roles in regulation of spermatogonia, but also is important for meiosis and
spermiogenesis in rodents (McLachlan et al. 2002; Haywood et al. 2003).
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Ovarian Development and Differentiation
The undifferentiated or bipotential gonadal ridge appears at approximately 10.5 dpc
between the coelomic epithelium and the mesonephros in the mouse. The fate of the
gonad is determined by both male-promoting and female-promoting signals. Sry, Sox9,
and fibrolast growth factor 9 (Fgf9) initiate testis differentiation in indifferent gonads.
Wingless-type member 4 (Wnt4) and R-spondin 1 (RSPO1) promote indifferent gonads
into ovary differentiation (Fig. 2) (DiNapoli and Capel et al., 2008). XX gonads do not
have Sry, so the female promoting signals shut down the male signals and initiate ovarian
development. The ovarian differentiation pathway involves the increase of the signaling
of WNT4 by RSPO1, which up-regulates β-catenin. β-catenin up-regulates WNT4 and
other proteins such as Follistatin (FST) (Edson et al., 2009). FST inhibits formation of
the XY-specific coelomic vessel in XX gonads. WNT4/FST signaling inhibits
downstream events of testis development. FST also plays a critical role in the survival of
germ cells in ovary.
Ovarian folliculogenesis
Autocrine, paracrine and endocrine factors contribute to ovarian folliculogenesis.
Besides oocytes, granulosa cells and theca cells also develope and play critical roles in
ovary. There are several steps in ovarian folliculogenesis: (1) formation of the primordial
follicle, (2) Maintenance of primordial follicles and initial recruitment (3) preantral
folliculogenesis, (4) theca formation and physiology, (5) antral follicle formation, (6) the
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preovulatory follicle, cumulus expansion, ovulation, and luteinization (Fig. 3) (Edson et
al., 2009).
Formation of the primordial follicle
After migration of PGCs, oogonia undergo mitotic proliferation. Mouse germ cells
are connected by intercellular bridges in the ovaries from 11.5 to 17.5 dpc (Pepling and
Spradling et al., 1998). Around 13.5 dpc in the female mouse, the first wave of oogonia
begin meiosis and finally arrest as diplotene oocytes close to birth (Bristol-Gould et al.,
2006). Individual oocytes in these nests lack surrounding somatic cells and majority of
the oocytes will undergo apoptosis. Cysts undergo apoptosis between 20.5-22.5 dpc in
mice, during which only about one third of the oocytes survive to form primordial
follicles (Pepling and Spradling, 2001, Edson et al., 2009). Some oocytes survive after
germ cell cluster breakdown. When those oocytes are individually surrounded by
squamous pre-granulosa cells, primordial follicle formation occurs. This is the first stage
of folliculogenesis and it occurs in the days immediately after birth in female mice
(Edson et al., 2009). During early postnatal period in the rodent, the primordial follicles
assemble. Primordial follicles consist of one oocyte and an incomplete layer of squamous
pre-granulosa cells. These primordial follicles are surrounded by stromal-interstitial cells
but no apparent theca cell layers or organized mesenchymal tissue (Skinner, 2005).
Maintenance of primordial follicles and initial recruitment
Follicle recruitment is subdivided into two categories. The first one is initial
activation of primordial follicles and it occurs throughout life until menopause. The
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second one is cyclic recruitment of a limited number of small follicles from the growing
cohort, from which a subset is selected for dominance and ovulation after puberty (Edson
et al., 2009). The majority of primordial follicles exist in a quiescent state in which the
oocyte is arrested in prophase I of meiosis. In sexually mature animals, follicles leave the
arrested pool and transform from primordial to primary follicles (Bristol-Gould et al.,
2006). Morphological changes in granulosa cells from squamous to cuboidal are the
histological marker for the transition from primordial to primary follicle. Several
transcription factors and signaling pathways regulate this early step in folliculogenesis.
NOBOX (newborn ovary homeobox), SOHLH1 (spermatogenesis and oogenesis helixloop-helix 1), and SOHLH2 are key transcription factors during the transition from
primordial to primary follicles (Edson et al., 2009). Transgenic mice lacking Nobox,
Sohlh1, or Sohlh2 have defects in the transition from primordial to primary follicle and
are infertile (Choi et al., 2008; Hao et al., 2008; Pangas et al., 2006; Rajkovic et al.,
2004). Nobox-/-, Sohlh1-/- Sohlh2-/- mice have the similar numbers of germ cell clusters
and primodial follicles as controls. However, by postnatal day 3, these transgenic mice
lack primary follicles and experience an early postnatal loss of oocytes. It is reported that
KIT ligand/KIT signaling contributes to the transition from primordial to primary follicle
and induces the PI3K/AKT pathway which lead to phosphorylation and inactivation of
forkhead box O3 (Foxo3). Foxo3 is a key oocyte factor critical for suppressing primordial
follicle activation (Castrillon et al., 2009).
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Preantral folliculogenesis
Preantral folliculogenesis is characterized by oocyte growth, granulosa cell
proliferation and acquisition of theca cell layer. Preantral follicle growth in mice starts at
10 to 12 days after birth when a cohort of developing follicles reaches the second stage of
folliculogenesis. Secondary follicles contain oocytes in the middle of their growth stage
which are surrounded by two or more layers of granulosa cells (Edson et al., 2009). The
communication between granulosa cells and oocytes is bidirectional and occurs
throughout follicular development (Eppig et al., 2002). Specifically, the oocyte depends
on its relationship with accompanied somatic granulosa cells to support its growth and
regulate the progression of meiosis. At the same time, oocytes stimulate granulosa cell
proliferation, differentiation, and function. For example, Oocyte-secreted members such
as the transforming growth factor β (TGF β) family, growth differentiation factor (GDF)9, and bone morphogenic protein (BMP)-15 play critical roles in early follicular
development (Dong et al., 1996; Dube et al., 1998; Elvin et al., 1999). These oocytederived paracrine factors also stimulate follicular somatic cell proliferation and
steroidogenesis (Elvin et al., 1999; Solovyeva et al., 2000).
Theca formation and physiology
Once the follicle develops two layers of granulosa cells, a layer of theca cells
differentiate to the outermost layer (Hirshfield, 1991a). The theca interna is a layer of
highly vascularized steroidogenic cells adjacent to the basal lamina, while the theca
externa is a loosely organized band of non-steroidogenic cells between the theca interna
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and the interfollicular stroma. The theca interna is composed of mitochondria with
tubular cristae, smooth endoplasmic reticulum, and abundant lipid vesicles (Magoffin,
2005). The theca externa contains fibroblasts, smooth muscle-like cells, and macrophages,
which are important during ovulation (Hirshfield, 1991b). Mouse follicles develop to the
large antral stage containing fully grown oocytes by 18–24 days after birth (Eppig et al.,
2002).
Antral follicle formation
During antral folliculogenesis, multiple small fluid-filled spaces combine to form a
single antral cavity. Two functionally distinct granulosa cell populations are separated by
the antral cavity. At the wall of the follicle the newly formed mural granulosa cells are
critical for steroidogenesis and ovulation while the antral granulosa cells surround the
oocyte which promotes its growth and development (Edson et al., 2009). FSH is essential
for antral follicular development (Kumar et al., 1997). FSH inhibits granulosa cell
apoptosis and follicular atresia and is necessary for antral granulosa cell proliferation,
estradiol production, and LH receptor expression (Chun et al., 1996; Richards, 1994).
The preovulatory follicle, cumulus expansion, ovulation, and luteinization
The majority of follicle populations in the growing pool undergo atresia and only a
few antral follicles in a developing cohort arrive at the preovulatory stage. Increased
follicular estradiol production increases pituitary LH and eventually induce the LH surge.
Preovulatory follicles

produce

luteinizing

hormone/choriogonadotropin

receptor

(LHCGR) at high concentrations in granulosa cells which enable them to respond to the
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LH surge. LH surge initiates downstream events leading to oocyte meiotic resumption,
cumulus expansion, follicle rupture and final terminal differentiation of the remaining
granulosa and theca cells to form the CL (Edson et al., 2009). Ovulation is a complex
LH-induced process that allows the release of an oocyte. The proper formation of an
extracellular hyaluronan (HA) rich matrix by the cumulus oocyte complex (COC) is
critical for ovulation. Genes induced by LH surge and essential for proper expansion are
hyaluronan synthase 2 (HAS-2) and cyclooxygenase-2 (COX-2). They control the
synthesis of hyaluronan and prostaglandins (Richards, 2005). After follicle rupture and
release of the cumulus-oocyte complex, the remaining granulosa and theca cells
differentiate to form the CL. The CL is an endocrine structure responsible for secreting
progesterone to stimulate the uterus and maintain pregnancy (Edson et al., 2009).
Vascular Endothelial Growth Factor
The Vegf family comprises five members, including Vegfa, Vegfb, Vegfc, Vegfd
(Figf, c-fos-induced growth factor) and placenta growth factor (Pgf). The significant one
of VEGF family is VEGFA (Tammela et al., 2005). It is an endothelial cell-specific
mitogen driven from arteries, veins and lympatics in vitro. VEGFA is an important
regulator of both developmental and tumorigenic angiogenesis (Grunstein et al., 2000). It
plays an essential role in embryonic vasculogenesis and angiogenesis in the mouse. It is
also involved in skeletal growth and endochondral bone formation and angiogenesis in
endocrine glands (Ferrara, et al., 2003; Ferrara, 2004).
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VEGFA gene
The human VEGFA gene is located on chromosome 6p21.3 and is organized in
eight exons, separated by seven introns (Houck et al, 1991; Tischer et al., 1991; Vincenti
et al., 1996) and can be alternatively spliced to produce pro-angiogenic (angiogenic) or
anti-angiogenic (inhibitory) isoforms by different factors (Fig. 4) (Harper and Bates,
2008). VEGFA is a heparin-binding homodimeric glycoprotein of 45 kDa (Ferrara and
Henzel, 1989).
VEGFA isoforms
VEGFA isoforms are generated by alternate splice-site selection in the terminal exon
(Nowak et al., 2008). Alternative exon splicing results in proangiogenic or angiogenic
polypeptides of 111, 121, 145, 148, 165, 183, 193, 189, and 206 and the anti-angiogenic
or inhibitory polypeptides 189b, 183b, 165b, 145b, 121b, acids for human (Ferrara et al.,
1991; Woolard et al., 2004; Harper and Bates, 2008). In rodent and domestic livestock,
VEGFA isoform contains one less amino acid than the human VEGFA isoforms
(Grunstein et al., 2000). Alternate 5’and 3’splice site selection in exons 6, 7 and 8
generate multiple isoforms (Haper and Bates, 2008). Two mRNA isoform families are
generated. Proximal splice-site selection (PSS) in exon 8 results in pro-angiogenic
VEGFAxxx isoforms (xxx is the number of amino acids), while distal splice-site
selection (DSS) results in anti-angiogenic VEGFAxxxb isoforms. SR protein splicing
factors including ASF/SF2, SRp40 and SRp55 regulate the VEGFA splicing. Both
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ASF/SF2 and SRp40 favored PSS, but SRp55 upregulated VEGFAxxxb (DSS) isoforms
(Nowak et al., 2008).
Angiogenic isoform
VEGFA angiogenic isoforms have the exon 8a (Nowak et al., 2008). VEGFA165
(VEGFA164 in rodent) was the first VEGFA isoform discovered in humans (Ferrara and
Henzel, 1989). VEGFA164 is the predominant VEGFA angiogenic isoform. It is a
multifunctional cytokine that is necessary for normal vascular development. It has
potential vascular permeable activity, stimulates endothelial cell migration and is
mitogenic for endothelial cells. It also re-programs endothelial cell gene expression and is
an endothelial cell survival factor (Nagy et al., 2003). VEGFA165 lacks the residues
encoded by exon 6, however, VEGFA121 does not have the residues encoded by exons 6
and 7 (Ferrara, 2004). In mouse, due to the possession of exon 7, VEGFA164 results in
increased heparin-binding affinity compared to VEGFA120. VEGFA188, containing both
exons 6 and 7, leads to a dramatic increase in charge and extracellular matrix (ECM)
association compared to the VEGFA164 and VEGFA120 (Grunstein et al., 2000).
Anti-angiogenic isoform
VEGFA anti-angiogenic or inhibitory isoforms have the exon 8b (Nowak et al.,
2008). In 2002, Bates et al. identified a VEGFAxxxb isoform: VEGFA165b in human (in
rodent VEGFA164b). They found that VEGFA165b inhibits VEGFA165-mediated
proliferation, migration of endothelial cells and vasodilatation of mesenteric arteries. The
results of their research suggest that VEGF165b may be anti-angiogenic. VEGFAxxxb
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isoforms are expressed in many tissues (Bates et al., 2002). VEGFAxxxb isoforms bind
to VEGFR2 (KDR), but lead a poorly activated kinase and weak downstream signal
transduction. VEGFA165b does not increase chronic microvascular permeability in vivo,
and reduces conditionally immortalized human glomerular endothelial cell monolayer
permeability in vitro. VEGFA165b also inhibits angiogenesis in vivo in the rat mesentery.
Moreover, VEGFA165b suppresses physiological angiogenesis in mammary tissue in
transgenic mice and pathological angiogenesis in murine tumour models (Harper and
Bates, 2008). All these studies suggest that VEGFAxxxb isoforms have an opposite
function compared to VEGFA angiogenic isoforms.
VEGFA receptors
VEGFA binds two related tyrosine kinases receptors: FMS-like tyrosine kinase1
(FLT1, also known as VEGFR1) and kinase insertion domain protein receptor (KDR,
also known as VEGFR2 and FLK1). The major mediator of the mitogenic, angiogenic
and permeability effects of VEGFA is KDR. Also KDR is involved in mediating
endothelial cell proliferation, survival and vascular permeability. In contrast, FLT1 may
play an inhibitory role by sequestering VEGFA and preventing its interaction with KDR.
In addition to these tyrosine kinases receptors, VEGFA also interacts with a family of
coreceptors: the neuropilins (Ferrara, 2004).
FLT1
Although Flt1 was the first VEGFR to be identified, the precise function of this
molecule is unclear. Recent evidence indicates that the controversial reports may be due
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to the fact that Flt1 functions and signaling properties are dependent on the
developmental stage and the cell type such as endothelial vs. hematopoietic cells (Ferrara,
et al., 2003; Ferrara, 2004). In response to VEGFA, Flt1 reveals a weak tyrosine
autophosphorylation (de Vries et al., 1992, Waltenberger et al., 1994). One study
reported that Flt1 activation causes inhibition of VEGFR2-dependent endothelial cell
proliferation and the pathway is PI3 kinase dependent (Zeng et al., 2001). Other studies
indicated that Flt1 interacts with different signal-transducing proteins and generate a
mitogenic signal (Landgren et al., 1998; Maru et al., 1998).
KDR
VEGFA angiogenic isoforms act primarily through VEGFR2 or KDR to initiate
multiple downstream signal pathways. VEGFA angiogenic isoforms stimulate robust
phosphorylation of tyrosine 1175, resulting in the activation of phospholipase Cγ (Fig. 5)
(Harper and Bates, 2008). Phospholipase Cγ activates protein kinase C which results in
the activation of Ras or Raf, mitogen-activated protein kinase (MAPK) and extracellularsignal-regulated kinase-1/2 (ERK1/2). The result of ERK phosphorylation is endothelial
cell proliferation. PLCγ also activates PKC via diacylglycerol (DAG) and then increase
concentrations of intracellular calcium (Shu et al., 2002). Besides PLCγ, the adaptor
molecule Shb binds to phosphorylated Tyr1175 of KDR. Tyr1173/1175 is coupled to
VEGFA-induced PI3K activation. PI3K then activates the serine/threonine kinase
AKT/PKB and mediates survival of the endothelial cells. AKT/PKB also regulates nitric
oxide (NO) production by phosphorylation and activation of endothelial NO synthase
(eNOS). ENOS regulates vascular permeability. The p38MAPK and FAK pathways are
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also postulated to affect actin reorganization and focal adhesion turnover to influence
migration. Heat-shock protein-27 (HSP27) is phosphorylated by p38MAPK. It is a
molecular chaperone that positively regulates VEGFA-induced actin reorganization and
migration. Several of these VEGFA signal transduction pathways may interact with each
other to initiate endothelial cell differentiation, migration, proliferation and survival
(Olsson et al., 2006).
Activation of KDR is phosphorylated by binding VEGFA anti-angiogenic isoforms;
however different tyrosine residues show that it may not simply be an inactive competing
inhibitor. Phospho-peptide mapping and site-specific phospho-antibody experiments
show that VEGFA anti-angiogenic isoforms only partially activate KDR suggesting a
partial intracellular rotation. This results in a rapid closure of the ATP binding site and
fast inactivation that lead to a poorly activated kinase and weak, transient
phosphorylation of ERK1 and ERK2 (Fig. 5) (Harper and Bates, 2008). This suggests
that VEGFA anti-angiogenic isoforms initiate a poor and weak downstream signal.
The Role of VEGFA in gonads
The role of VEGFA in the ovary
Angiogenesis is a key aspect of normal cyclical ovarian function. Both follicular
growth and the development of the CL are dependent on the proliferation of new
capillary vessels (Ferrara, 2004). It is demonstrated that the VEGFA mRNA expression is
also temporally and spatially associated with the proliferation of blood vessels in the
ovary (Phillips et al., 1990; Ravindranath et al., 1992). VEGFA stimulates
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neovascularization, regulates vascular permeability and is one of the key factors that
regulate angiogenesis in the ovary (Kaczmarek et al., 2005).
Follicle activation is related to increased VEGFA and increased blood vessel
extension (Mattioli et al., 2001). One in vitro study showed that direct ovarian
administration of VEGFA significantly increased the number of preantral follicles in the
rat ovary suggesting that VEGFA regulates the early follicle growth (Danforth et al.,
2003). Other research has demonstrated that endogenous VEGFA is essential for
primordial follicle survival in the rodent (Roberts et al., 2007). Iijima et al., demonstrated
that VEGFA angiogenic isoform promoted ovarian follicular angiogenesis, stimulated
follicular development and increased the numbers of oocytes ovulated in mature cycling
rats (Iijima et al., 2005).
VEGFA promoted the primary into secondary follicle transition in bovine follicles
activated in vitro. Thus, VEGFA plays a stimulatory role in early preantral follicular
growth in cattle (Yang and Fortune et al., 2007). In nonhuman primates, inhibition of
VEGFA and KDR either suppresses follicular development or prevents ovulation
(Zimmermann et al., 2001; Zimmermann et al., 2002). Zimmermann’s research showed
that injection of VEGFA antagonist into the pre-ovulatory follicle in rhesus monkey
caused half of the animals not to ovulate. This indicates VEGFA may also stimulate
ovulation in addition to follicle progression (Zimmermann et al., 2002).
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Our laboratory’s finding on the role of VEGFA in the ovary
Recently, our laboratory published some findings about the role of VEGFA in the
ovary. We demonstrated that VEGFA and KDR were expressed in pregranulosa and
granulosa cells of all follicle stages and in theca cells of advanced-stage follicles. Rat
ovaries treated with VEGFA receptor signal transduction inhibitor had a 94% reduction
in vessel density. And these ovaries had more primordial follicles, fewer early primary,
transitional, and secondary follicles, and greater total follicle numbers compared with
control ovaries. The results indicated that VEGFA is involved in primordial follicle
activation, maturation and survival (McFee et al., 2009). Another study showed that rat
ovaries treated with VEGFA164 or VEGFAxxxB antibody had vascular development
increased by 93%. VEGFA164 treated ovaries had fewer primordial follicles and more
developing follicles than controls. Ovaries treated with VEGFAxxxB antibody had fewer
primordial and earlier primary follicles and more primary, transitional, and secondary
follicles compared with controls. The data suggested that VEGFA proangiogenic isoform
promotes follicular development (Artac et al., 2009).
The role of VEGFA in the testis
Overexpression of VEGFA164 in the testis and epididymis of transgenic mice
resulted in upregulation of VEGFA receptors in the endothelial cells, certain
spermatogenic cells and the Leydig cells and caused infertility. The VEGFA164
overexpression in testis and epididymis resulted in spermatogenic arrest. This indicated
that VEGFA may regulate male fertility (Korpelainen et al., 1998). One study on male
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roe deer showed the strength of VEGFA angiogenic isoforms mRNA expression is
dependent on the season. It reached its highest level at the peak of spermatogenesis
during the pre-rutting period and had its nadir at the end of the rut when involution
already began. These results suggest that VEGFA angiogenic isoforms may directly
affect the regulation of spermatogenesis (Wagener et al., 2010).
Our laboratory’s finding on the role of VEGFA in the testis
Our laboratory has demonstrated that VEGFA is critical for both vascular
development and testicular cord formation. Both Treatment with Je-11 (a VEGFA
antagonists) and VEGFR-TKI (a VEGFA receptor signal transduction inhibitor)
perturbed cord formation and inhibited vascular density in rat cultured testis. Rat E13
testes were treated with a phosphoinositide 3-kinase (PI3K) pathway inhibitor which
resulted in inhibition of both vascular density and cord formation. These studies suggest
that VEGFA potentially works through the PI3K pathway to promote testicular cord
formation and vascular density during testis morphogenesis (Bott et al. 2006). Treatment
of E13 mouse organ culture testes with VEGFA angiogenic isoform or an antibody to
antiangiogenic isoforms (anti-VEGFAxxxB) resulted in less organized and poorer
seminiferous cords compared with controls. In addition, VEGFA angiogenic isoform and
anti-VEGFAxxxB also increased the vasculature density in the mouse culture testes. The
results from these studies suggest that an imbalance in the production of VEGFA proversus anti-angiogenic isoforms may impair testis morphology and development. Both
VEGFA angiogenic and inhibitory isoforms are important for development of vasculature
and seminiferous cords in rat testes (Baltes-Breitwisch et al., 2010). Recently, we
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demonstrated that KDR was expressed in germ cells E16, E17, P4, and after P20 in
mouse testis. KDR-LacZ testis organ cultures treated with VEGFR-TKI had reduced
numbers of KDR-LacZ stained cell in developing testes; this indicates decreased
migration of KDR-expressing endothelial cells from the mesonephros to the testis. Thus,
the VEGFA signal transduction inhibitor reduced the endothelial cell migration during
testis formation (Bott et al., 2010). Taken together, these studies suggest that VEGFA
and its receptor are involved in the development of vasculature and seminiferous cords in
both rat and mouse testes.
Conclusion
Vascular endothelial growth factor is one of the key factors regulating angiogenesis
in the ovary. It has been demonstrated to be a potential regulator of follicle development
and ovulation (Kaczmarek et al., 2005; Danforth et al., 2003). Since VEGFA is produced
in numerous ovarian compartments and its important role in ovarian vascular physiology,
we hypothesized that production of VEGFA by granulosa cell is critical for normal ovary
morphogenesis and function. The objective of my first project is to determine the in vivo
effects of granulosa-cell specific VEGF loss on ovary function and morphogenesis.
Besides the role in ovary, VEGFA also plays a critical role in testis development.
VEGFA and its receptor KDR are present during testis morphogenesis. It has been
demonstrated that VEGFA is involved in the development of vasculature and
seminiferous cords in rodent testes and supports germ cell survival (Bott et al., 2006,
Caires et al., 2009; Baltes-Breitwisch et al., 2010). We hypothesized that VEGFA,
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produced by Sertoli cells, plays an important role in testis morphogenesis and function.
The objective of my second project is to determine the in vivo effects of Sertoli cellspecific VEGFA loss on male reproductive organs’ function and morphogenesis.
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stage 5:

Urogenital ridge Indifferent gonad Sex determination Cord formation Development
of functional testis

Fig.1 Morphology stages that occur during testis differentiation from genital ridge
formation to cord formation and cell proliferation in the mouse with stage in number of
tail somites (ts) and dpc (figure adapted from Cupp and Skinner, 2005)
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Fig.2 Model of Opposed Signals in Mammalian Sex Determination (figure adapted from
DiNapoli and Capelm, 2008)
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Fig.3 Major stages of mammalian folliculogenesis (figure adapted from Edson et al.,
2009).

Fig.4 Protein and mRNA products of human VEGF-A folliculogenesis (figure
adapted from Harper and Bates, 2008).
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Fig.5 Signalling pathways downstream of vascular endothelial growth VEGFA
angiogenic and inhibitory isoforms (figure adapted from Harper and Bates, 2008)
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Chapter 2
Granulosa cell-specific Vascular Endothelial Growth Factor A (VEGFA) loss using
pDMRT-1 Cre alters ovarian morphogenesis, reduces plasma estrogen
concentrations and impairs fertility
Abstract
VEGFA is a critical regulator of vascular physiology in the ovary and plays an
important role in the regulation of follicular growth. The objective of the current study
was to evaluate effects of granulosa cell-specific production of VEGFA isoforms on the
vascular development and ovarian morphogenesis. The pDmrt1 gene is expressed in the
indifferent gonad in precursor granulosa and Sertoli cells and in some specific germ cell
lineages. We used a pDmrt1-cre mouse crossed to a floxed VEGFA mouse to determine
potential phenotypes in female granulosa-cell (VEGFA-DGranG) specific knockouts.
Ovaries, uterus, kidneys and adrenals were collected from adult mice, and weighed
(control n=11, VEGFA-DGranG n=10). The weight of ovaries from VEGFA-DGranG
was significantly smaller than that of the control (0.0144+0.0014 VS 0.0183+0.0009 g, P
< 0.05). Ovaries from VEGFA-DGranG had reduced numbers of CL/ovary than the
control (2.25+0.4119 VS 4+0.4629, P < 0.05) and two of those VEGFA-DGranG females
had abnormal CL morphology. Serum estradiol concentrations in the VEGFA-DGranG
mice were 55% of control mice (48.83+9.58 VS 89.48+13.17 pg/ml, P < 0.05). The
number of days mated until parturition was 12 days longer in VEGFA-DGranG X
VEGFA-DSertG pairs versus control females mated with control males (38.27+4.65 VS
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26.18+2.17 days, P < 0.05). Therefore, we conclude from these data that absence of both
VEGFA pro-angiogenic and anti-angiogenic isoforms may alter ovarian morphogenesis,
follicle development and ovulation resulting in impaired fertility in female mice.
Introduction
In mammals, female reproductive life span depends not only on the size of the
primordial follicle pool, but also on the complement of follicles and development of those
follicles during the peripubertal period. Abnormalities in either primordial follicle pool
development or follicle progression may result in impairment of ovarian function
(Mazaud et al., 2002). There is intense angiogenesis and increased permeability of blood
vessels during follicular development, ovulation and formation of the corpus luteum. The
availability of an adequate vascular supply to provide endocrine and paracrine signals
have been shown to play a key role in the regulation of follicle growth (Redmer and
Reynolds, 1996). Angiogenesis plays an important role in follicular development with
independent regulation of vasculature within each follicle contributing to its development
(Fraser, 2006). VEGFA is one of the key factors regulating angiogenesis in the ovary.
VEGFA stimulates neovascularization, vascular permeability, acts as a survival factor
and can also stimulates proliferation of vascular and nonvascular cells.
Several studies have demonstrated that VEGFA is important in the growth of
capillary vessels around follicles in the ovary and it also promotes development of
ovarian follicles in rats and mice (Shimizu et al., 2003; Kaczmarek et al., 2005; Danforth
et al., 2003; Quintana et al., 2004), including both preantral and antral follicular
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development (Shimizu et al., 2007; Danforth et al., 2003). VEGFA production is critical
in the control of follicle growth and activity (Mattioli et al., 2001). Kosaka et al. reported
that VEGFA inhibited bovine granulosa cell apoptosis. These results demonstrated that
VEGFA not only acts in vascular formation but also functions as a survival factor for
ovarian follicles (Kosaka et al., 2007).
In addition to development of the vasculature and apoptosis, VEGFA also appears to
regulate ovulation. In vivo studies showed that inhibition of VEGFA and VEGF receptor2 can inhibit follicular development or prevent ovulation (Zimmermann et al., 2001;
Zimmermann et al., 2002). Furthermore, injection of a VEGFA antagonist into the preovulatory follicle in rhesus monkey resulted in half of the animals failing to ovulate with
the large follicles of these females becoming luteinized (Zimmermann et al., 2002). Thus,
in addition to follicular development VEGFA also appears to affect ovulation.
The Vegf family comprises five members, including Vegfa, Vegfb, Vegfc, Vegfd
(officially called Figf, c-fos-induced growth factor) and placenta growth factor (Pgf). The
significant one of Vegf family is Vegfa in the ovary. The Vegfa gene has eight exons and
can be alternatively spliced by different factors to produce angiogenic or inhibitory
isoforms. VEGFA angiogenic or inhibitory isoforms have opposite functions (angiogenic
isoforms promote vascular development while anti-angiogenic isoforms inhibit vascular
development). To initiate biological effects, VEGFA binds two related tyrosine kinase
receptors: FMS-like tyrosine kinase 1 (FLT1, also known as VEGFR1) and kinase insert
domain receptor (KDR, also known as VEGFR2 and FLK1). The primary receptor is
KDR (Ferrara et al., 2003). KDR is the major mediator of the mitogenic, angiogenic and

41

permeability enhancing effects of VEGFA. KDR is involved in mediating endothelial cell
proliferation, survival and vascular permeability, whereas FLT1 might play an inhibitory
role by sequestering VEGFA, and preventing its interaction with KDR (Ferrara et al.,
2004). Roberts et al. reported ovarian administration of antibodies to KDR resulted in
significant depletion of primordial follicle numbers, whereas anti-FLT1 antibodies did
not (Roberts et al., 2007). This is consistent with KDR receptor as the primary mediator
of VEGFA action in the ovary and that the FLT1 receptor might be a decoy for VEGFA.
In the human ovary, VEGFA is produced by the theca and granulosa cells
(Yamamoto et al., 1997; Roberts et al., 2007). Our laboratory has demonstrated that
VEGFA and its receptors are also localized to pre-granulosa and granulosa cells of all
follicle stages and to theca cells of advanced-stage follicles in rat (McFee et al., 2009).
An in situ study showed the in vivo expression of VEGFA in different cell types
including theca, cumulus, granulosa and luteal cells in mouse ovary (Shweiki et al.,
1993). Independent of its angiogenic effects, VEGFA may also be important in the
regulation of follicle growth with direct effects on granulosa cells. Rat ovaries treated
with VEGFA receptor-tyrosine kinase inhibitor had vascular development reduced by 94%
and follicle progression was blocked since there were more primordial follicles, and
fewer early primary, transitional, and secondary follicles compared to controls. This
study demonstrated a novel role for VEGFA in the recruitment of primordial follicles into
the growing follicle pool, as well as a potential survival factor for primary and later-stage
follicles through vascular dependent and vascular-independent mechanisms (McFee et al.,
2009). Further studies from our laboratory demonstrated that treatments with both
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neutralization of anti-angiogenic VEGFA isoforms and pro-angiogenic isoform VEGFA
164 enhanced vascular and follicular development in perinatal rat ovaries. These results
suggest that VEGFA isoforms are involved in vascular development and follicle
activation in the rat ovary with pro-angiogenic isoforms stimulating follicle progression
and anti-angiogenic isoforms inhibiting or arresting follicle development (Artac et al.,
2009).
Thus, VEGFA is an important regulator of ovarian vascular physiology and is
produced in numerous ovarian compartments. In the current study, we hypothesized that
production of VEGFA isoforms (both pro and anti-angiogenic) by granulosa cells is
critical for normal ovary morphogenesis and function. Therefore, the objective of present
study was to determine the in vivo effects of granulosa-cell specific VEGFA loss on
ovary function and morphogenesis.
Materials and methods
Animals
Granulosa cell-specific VEGFA KO mice were obtained by using the Cre-loxP
approach. We used a line of VEGFAloxp/loxp mice (Gerber et al., 1999) from Napoleon
Ferrara at Genentech to mate with pig Dmrt1-cre mice (Boyer et al., 2002) to develop
granulosa and Sertoli cell-specific VEGFA knockout mice (breeding scheme in Appendix
A). The Dmrt1 gene is expressed in the indifferent gonad at 10.5 dpc in precursor cells
that differentiate into Sertoli and granulosa cells. By 12.5 dpc, Dmrt1 is expressed in
Sertoli cells and germ cells in XY gonads and in ovarian somatic cells and germ cells.
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Dmrt1 is evident in Sertoli cells at all ages examined and absent in ovarian somatic cells
from 13.5 dpc. Expression of Dmrt1 in primordial germ cells increases through 13.5 dpc
and absent by 15.5 dpc. Sexual differences in germ cell Dmrt1 were detected after birth,
when it was detected only in spermatogonia of the testis (Lei et al., 2007). The pDmrt1
gene is expressed similar to mouse Dmrt1 (Boyer et al., 2002). In our VEGFA-DGranG
mouse, VEGFA gene exon 3 was flanked by two loxp sites and Cre, driven by pig Dmrt1,
bound and deleted the DNA sequence between the two flox. The VEGFA was not
expressed in the cells where Dmrt1 is present. We used Cre-negative VEGFAloxp/loxp or
VEGFAloxp/+ mice as controls and Cre-positive VEGFAloxp/loxp mice as KO (VEGFADGranG). Ovaries, uterus, kidneys and adrenals were collected from female adult mice
that were cycling, non-pregnant and were at random stage of the estrous cycle (control
n=11, VEGFA-DGranG n=10) and weighed. All the female were approximately 250 days
of age. All animal protocols were approved by the University of Nebraska Institute of
Animal Care and Use Committee (IACUC) in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals.
Genotyping:
DNA was extracted from tail samples and used for genotyping via polymerase chain
reaction (primers and PCR programs are listed in Appendix B). Genomic DNA was
extracted from tails of mice by proteinase K digestion and followed by 6M NaCl
extraction and ethanol precipitation (Bott et al., 2010).
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Embedding, Histology and staining (hemotoxylin and eosin staing; H&E):
Ovaries were fixed in Bouin’s solution and rinsed in 70% ethanol. Embedding was
performed according to the standard procedures (McFee et al., 2009; Bott et al., 2010).
Prior to paraffin embedding, ovaries were rinsed in 100% ethanol 1 hour for 3 times and
CitriSolve (Fisher Scientific, Fairlawn, IL) 1 hour for 3 times. Embedded tissues were
sectioned (5 µm) and the slides were placed in an incubator (37°C) overnight. Sectioned
ovaries were deparaffinized, stained with hematoxylin for 1 min (VWR International,
West Chester, PA) and eosin for 30 min (Ricca, Arlington, TX), dehydrated and mounted.
Immunohistochemistry:
Sectioned tissues were deparaffinized, rehydrated, and microwaved in 0.01 M
sodium citrate to boil for 15 min. Then, tissues were cooled for 1 h and rinsed in 3%
hydrogen peroxide in methanol for 20 min. Sections were blocked with 10% normal goat
serum in PBS for 30 min at room temperature and washed in PBS 3 times.
Immunohistochemistry was performed according to the standard protocol in our
laboratory (Mcfee et al., 2009). The Cyp11a1 primary antibody (catalog number:
ab78416; Abcam, Cambridge, Mass., USA) was diluted in 1:200 in 10% normal goat
serum. As a negative control, serial sections were processed without primary antibody.
Biotinylated goat anti-rabbit secondary antibodies were diluted 1:300. Secondary
antibody was detected using aminoethyl carbazole (AEC) chromagen substrate solution
(ZYMED Laboratories, SanFrancisco, CA). Sections were counterstained with
hematoxylin to determine cell types that were stained with respective antibodies.
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RNA isolation:
Total RNA from ovaries was extracted using Tri-Reagent according to
manufacturer’s protocol (Sigma, St. Louis, MO). After isolation total RNA was dissolved
in 20 µl diethyl pyrocarbonate (DEPC) water. The extracted RNA was diluted 1:14 in
DEPC water and the concentration was determined by spectroscopy at 260nm using the
Lambda EZ 150 (Perkin Elmer).
Reverse Transcription (RT)-PCR:
Before RT-PCR, 1 µl of RNA was removed from each sample to a new tube with 15
µl DEPC water to be used as ―No RT‖ to detect the residual genomic DNA. RT was
performed on 5 µg of template using SuperScript II (Invitrogen, Carlsbad, CA) according
to the manufacturer’s recommended protocol (McFee et al., 2009; Bott et al., 2010). RT
samples were incubated in 65°C with 2 µl of oligo (dT) 15 primer (Promega), 2 µl
dexoxynucleotide triphosphates (Fermantas; 10 mM dNTP mix), 3.8 µl DEPC water, and
then immediately chilled on the ice. After that, 1 µl SuperScript II reverse transcriptase
(200 units/µl; Invitrogen, Carlsbad, CA), 3.2 µl of stand buffer (Invitrogen, Carlsbad,
CA), 2 µl 0.1 M DL-dithiothreitol (DTT) (Invitrogen, Carlsbad, CA), 1 µl DEPC water
were added into each sample. The samples were incubated at 42°C for 1 hour followed by
15 min at 70°C to inactivate the reverse transcriptase. The cDNA was stored at 20°C for
subsequent real time-PCR.
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Quantitative RT- PCR (QRT-PCR):
Quantitative real-time PCR primers and probes used in the experiment were shown
in table 1. Glyceradehyde-3-phosphate dehydrogenase (Gapdh) gene is a housekeeping
gene and used as a control for RNA amplification. QRT-PCR was performed in 364 well
plates (Axygen Scientific, Union City, CA) with an adhesive cover film (VWR, Scientific
Products, North Kansas City, MO). Gapdh, Bcl-2 and Bax were performed with 10 µl
Taqman universal Master Mix (Applied Biosystem, Foster City, CA), 1 µl cDNA, 0.5 µl
of each forward and reverse primers, 2 µl probe, and 6 µl DEPC to make up the reaction
volume to 20 µl. Foxo3a, Gdnf-9, Cyp17a1 and Cyp11a1 were performed with 10 µl
SYBR Green PCR Master Mix (Applied Biosystem, Foster City, CA), 1 µl cDNA, 0.6 µl
of each forward and reverse primers, and 7.8 µl DEPC to make up the reaction volume to
20 µl. Experimental and Gapdh PCRs were carried out in separate wells in triplicate. An
arbitrary value of template was assigned to the highest standard and corresponding values
were assigned to the subsequent dilutions. These relative values are plotted against the
threshold value for each dilution to generate a standard curve. The relative amount for
each experimental and Gapdh triplicate was assigned an arbitrary value based on the
slope and y-intercept of the standard curve. The average of the experimental triplicate is
divided by the average of the Gapdh triplicate, and the resulting normalized values are
used for statistical analysis (McFee et al. 2009).
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Blood collection and Hormone Enzyme-Linked Immunosorbent Assay (ELISA):
Blood was collected at the time of euthanization and put into tubes with 20 µl EDTA
solution (Fisher Scientific Co., Fair Lawn, NJ). Blood sample was immediately
centrifuged at 1250 X g for 10 mins, the plasma was removed into a new tube and stored
in -80°C. Estradiol level was determined by Estradiol ELISA kit (Alpha Diagnostics
International Inc., San Antonio, TX; Cat. No.1920). Samples remained undiluted and
were run according to the manufacture’s direction. Standard curve samples were made of
10 pg, 50 pg and 150 pg to ensure that all samples were on the curve. Assay sensitivity
was 10 pg/ml. The progesterone concentration was determined by Progesterone ELISA
kit (Alpha Diagnostics International Inc., San Antonio, TX; Cat. No. 1860). Standard
curve samples were made of 0.5 ng/ml, 1 ng/ml, 5 ng/ml, 10 ng/ml, 30 ng/ml. Assay
sensitivity was 0.2 ng/ml. Testosterone concentration was determined by Testosterone
ELISA kit (Alpha Diagnostics International Inc., San Antonio, TX; Cat. No.1880).
Standard curve samples were made of 0 ng/ml, 0.5 ng/ml, 1 ng/ml, 2.5 ng/ml, 10 ng/ml
and 20 ng/ml. Assay sensitivity was 0.125 ng/ml.
Statistical analysis:
All data were analyzed by two-sample t-test using SAS software (SAS institute,
Cary, NC). Differences in data were considered statistically significant at P < 0.05.
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Results
Phenotypes in the female ovary of VEGFA-DGranG mice:
The ovarian weight and morphology were used to evaluate the effect of granulosa
cell-specific VEGFA loss on female ovary. As shown in figure 2A, the weight of ovaries
was significantly decreased for VEGFA-DGranG females compared with the controls
(0.0144+0.0014 VS 0.0183+0.0009 g, P < 0.05). To assess the effect of granulosa cellspecific VEGFA loss on ovary histological morphology, ovaries were stained by H&E.
VEGFA-DGranG mice had ovaries with fewer antral follicles and corpus lutea (CL), and
two VEGFA-DGranG mice had abnormal morphology in structures that appeared to be
CL (fig. 1). To examine the effect of granulosa cell-specific VEGFA loss on ovulation,
we counted the number of CL in the ovary. Cyp11a1 was used as a marker to count
numbers of CL/ovary (fig. 3A, B, C). As shown in figure 3D, the number of CL/ovary
from VEGFA-DGranG mice was significantly less than that from control mice
(2.25+0.4119 VS 4+0.4629, P < 0.05). These results indicated that there were reduced
ovulation rate potentially caused by reductions in production of antral follicles on the
ovary of VEGFA-DGranG mice.
Effect of Granulosa cell-specific VEGFA loss on female mouse uterus, kidneys and
adrenals:
To test whether Granulosa cell-specific VEGFA loss affects other organs in the
mouse, we compared the weight of those organs between VEGFA-DGranG and control
females. There were no significant differences on the weight of uterus (0.1094+0.0094
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VS 0.1036+0.0103 g, P =0 .68, fig. 2B), kidneys (0.3782+0.0157 VS 0.4231+0.0208 g, P
= 0.13, fig. 2C) or adrenals (0.0082+0.0007 VS 0.0087+0.0005 g, P = 0.54, fig. 2D)
between VEGFA-DGranG mice and control mice. So only ovarian weight was affected
by granulosa cell specific VEGFA loss.
Effect of Granulosa cell-specific VEGFA loss on 17 beta estradiol, progesterone, and
testosterone concentrations:
Blood collected was used to measure circulating hormone levels. Serum 17βestradiol concentrations in the VEGFA-DGranG females were 55% of those in controls
(48.83+9.58 VS 89.48+13.17 pg/ml, P < 0.05, fig. 4A). There was no significant
difference in progesterone concentrations between the VEGFA-DGranG and control
females (145.49+31.81 VS 135.39+15.66 ng/ml, P = 0.78, fig 4B). Serum testosterone
was not significantly different between the VEGFA-DGranG mice and control mice
(0.12+0.02 VS 0.16+0.02 ng/ml, P = 0.26, fig 4C).
Effect of Granulosa cell-specific VEGFA loss on gene expression in ovary:
Because one study demonstrated that injection of a VEGFA inhibitor to prepubertal
eCG treated rats significantly increased the levels of Bax and decreased the levels of Bcl2 protein content of antral follicle (Abramovich et al., 2006). We evaluated the effect of
Bcl-2 and Bax mRNA expression in Granulosa cell VEGFA loss within the ovary. Bcl-2
and Bax mRNA in VEGFA-DGranG were not significant different from control (Bcl-2:
6.51+2.27 VS 11.07+4.50, P = 0.53, fig. 5A; Bax: 5.76+2.57 VS 4.41+1.10, P = 0.56, fig.
5B). In addition, there was no difference in ratio of Bcl-2 to Bax (3.36+2.60 VS
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87.84+73.10, P = 0.28, fig. 5C). But Bcl-2 averages were 2 fold higher in controls versus
VEGFA-DGranG KO’s and the ratios of Bcl-2 to Bax was 26 fold higher in controls.
Thus, variation in our control’s severely affected our ability to detect differences in this
gene and gene ratio. Forkhead boxo3a (Foxo3a) is a transcription factor and arrests
follicle progression. Foxo3a mRNA was not significantly different between VEGFADGranG ovary and control (8.80+3.62 VS 4.99+1.24, P = 0.23, fig. 5D). Nor was an
oocyte marker, growth differentiation factor (Gdf-9) (Sun et al., 2010) mRNA different
between VEGFA-DGranG ovary and control (148.91+59.89 VS 223.45+70.99, P = 0.53,
fig. 5E). Cyp11a1 converts cholesterol to pregnenolone and Cyp17a1 converts
pregnenolone to androgen. As shown in figure 5F and 5G, Cyp17a1 (3851.28+3079.76
VS

1340.91+

436.37,

P

=

0.48)

and

Cyp11a1

(82,659.33+37,082.03

VS

8,509,574.76+8,420,312.39, P = 0.48) mRNA in the ovary between VEGFA-DGranG
and control was not statistically significant different. Cyp11a1 mRNA in VEGFADGranG ovary is 103 fold higher in controls; but the variation in control’s Cyp11a1 gene
expression and reduced numbers of KOs inhibited our ability to detect differences in this
gene.
Effect of Granulosa cell-specific VEGFA loss on fertility:
To determine whether Granulosa cell-specific VEGFA loss has any effect on
fertility, VEGFA-DGranG females were mated with males that had VEGFA knocked out
in Sertoli and some germ cells (VEGFA-DSertG). There were 5 KO groups and 9 control
groups. We found that the number of days for VEGFA-DGranG females mating with
VEGFA-DSertG males until parturition was (12 days) longer than that for control
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females mating with control males (38.27+4.65 VS 26.18+2.17 days, P < 0.05, fig. 6).
This indicated that the rate of ovulation in female mice or sperm quantity in the males
may be affected by VEGFA-specific granulosa and Sertoli knock outs. There was no
significant difference in number of litters/female in approximate 2 months, pups/litter
between VEGFA-DGranG females with VEGFA-DSertG males group and control
females with control males group (2.20+0.37 VS 1.67+0.24 litter numbers/female in
approximate 2 months, P = 0.23; 8.18+0.74 VS 7.64+0.40 pups/litter, P = 0.50).
Discussion
In the current study, we determined that VEGFA loss in granulosa cells increased
the time from mating to parturition, reduced number of antral follicles, numbers of
CL/ovary and reduced estrogen concentrations by 55%. Thus, these females were
subfertile due to the loss of both angiogenic and anti-angiogenic VEGFA isoforms. The
reduction in fertility may be due to less overall follicle progression and maturation,
reduced ovulations, or through reduced production of estrogen. The reduction in follicle
maturation is supported by the smaller ovarian weight and reduction in estrogen
concentrations in blood; suggesting that less follicles reached the antral stage where
estrogen production is maximal.
The formation of a dense capillary network (angiogenesis) in the ovary enables the
hormone-producing cells to obtain the oxygen, nutrients and also precursors necessary to
synthesize and release different hormones essential for maintenance of the ovarian
functions (Kaczmarek et al., 2005). Loss of VEGFA in granulosa cells may reduce
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angiogenesis, the blood supply for oxygen, nutrients and influence the growth of the
ovary and follicle maturation. The reduction in ovarian weight in the VEGFA-DGranG
females may be due to a decline in maturation of follicles and this is also supported by
the dramatic reduction in estrogen that was present in these females.
Follicles are surrounded by somatic cells (granulosa and theca cells) and can be
classified into preantral (primordial, primary and secondary) and antral (tertiary and
preovulatory) follicles. Quiescent primordial follicles and slow growing preantral
follicles do not have a vascular supply of their own, but instead rely on vessels in the
surrounding stroma (Brunol et al., 2009). Stromal blood vessels transport nutrients and
oxygen to primordial and primary follicles through passive diffusion. Follicular growth is
associated with the development of an individual capillary network and continued
angiogenesis to nourish the rapidly expanding follicle. Some types of infertility may be
associated with the disturbance of follicular angiogenesis, which results in inadequate
development (Fraser, 2006). Acquisition of an adequate vascular supply is probably a
limiting step in the selection and maturation of the dominant follicle destined to ovulate
(Stouffer et al., 2001).
Our lab also demonstrated that VEGFA is involved in primordial follicle activation,
maturation and survival (McFee et al., 2009). Rat ovaries treated with VEGFA_164 or
VEGFAxxxB antibody had a 93% increase in vascular density. VEGFA_164 treated
ovaries were composed of fewer primordial follicles (stage 0) and more developing
follicles (stages1–4) than controls. Ovaries treated with VEGFAxxxB antibody had fewer
primordial and early primary follicles and more primary, transitional, and secondary
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follicles compared to controls. These data suggested that VEGFA proangiogenic isoform
promote follicle development, and in constrast, VEGFA anti-angiogenic isoforms
maintain primordial follicles in an arrested state. Removal of VEGF anti-angiogenic
isoforms allows for increased progression of primordial follicles to the developing
follicle pool (Artac et al., 2009). VEGFA also promotes the primary into secondary
follicle transition in bovine follicles activated in vitro stimulating follicular growth in
cattle (Yang and Fortune et al., 2007) as well as rodents.
In our study, ovarian weight in VEGFA-DGranG mice was smaller than that of
control. This suggests granulosa cell-specific VEGFA loss within mouse ovary does
affect ovarian size through reduction of follicle development and/or maturation. In
previous studies direct injection of VEGFA in the rat ovary increased the number of
antral follicles and promoted the development of antral follicles by inducing the
formation of theca vasculature. The results of VEGFA treatment were increased crosssectional area of ovaries with VEGFA injection compared to controls (Shimizu et al.,
2007). Another reason for the reduced ovarian size in the VEGFA-DGranG females is
due to the reduced CL and potentially a decrease in ovulation rate. An in vivo study
showed that the VEGFA angiogenic isoform promoted ovarian follicular angiogenesis
leading to stimulatory effects on subsequent follicular development and numbers of
oocytes ovulated in mature cycling rats (Iijima et al., 2005). Inhibition of VEGFA and
KDR suppress follicular development and ovulation (Zimmermann et al., 2001;
Zimmermann et al., 2002). The fewer CL in VEGFA-DGranG may be caused by fewer
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antral follicles and less ovulation in those mice. Even though CL numbers were reduced
there was no significant difference in progesterone concentrations in the serum.
Our previous data showed that rat ovaries treated with VEGFA 164 or VEGFAxxxB
antibody increased the vascular density (Artac et al., 2009). In newly formed CL,
VEGFA mRNA and protein expression are observed in the granulosa- and theca-derived
luteal cells. In several species, expression levels are higher in granulosa-derived cells
than that in theca-derived luteal cells (Kamat et al., 1995; Endo et al., 2001;
Boonyaprakob et al., 2003; Kaczmarek et al., 2005). Highly expressed VEGFA in
granulosa-derived luteal cells may act as a chemoattractant for endothelial cells in order
to initiate the invasion of avascular granulosa layer establishing an extensive capillary
network that nourishes the development of CL and assists in the maintenance of luteal
function throughout its’ lifespan (Kaczmarek et al., 2005). In the present study, two
ovaries of VEGFA-DGranG mice showed abnormal morphological structure in CL which
appeared to be devoid of vasculature. It is possible that granulosa cell-specific VEGFA
loss affects the establishment of capillary network in developing CL and consequently
influences the structure of CL.
Estrogens are produced primarily by developing follicles in the ovary (Yang et al.,
2000). Other tissues such as the liver, adrenal glands, and the breast also produce
estrogens in a smaller amount. Granulosa cells in the ovary can convert androstenedione
to estrone or estradiol. The aromatase knockout mouse, the estrogen β receptor knockout
mouse, and the estrogen α receptor knockout mouse have demonstrated that estrogen
enhances the number of follicles progressing to the early antral stage (Fisher et al., 1998;
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Krege et al., 1998; Schomberg et al., 1999; Danforth et al., 2003). Furthermore, a
positive relationship between VEGFA and E2 concentrations in the gilt follicular fluid
suggest a possible cause-and-effect relationship (Mattioli et al., 2001) with VEGF
stimulating estrogen production by increasing vascular permability to cholesterol and
increasing signal transduction pathways activating enzymes that are critical to estrogen
production. One study showed that serum 17β-estradiol concentration in rats treated with
VEGFA120 and 164 were significantly higher than that in the control rats, indicating that
VEGFA120 and 164 may indirectly stimulate the production of 17β-estradiol via
granulosa cells (Iijima et al., 2005). In our study, serum 17β-estradiol level in the
VEGFA-DGranG was significantly lower than that in the control. Our results indicated
that loss of VEGFA in granulosa cell may inhibit the production of 17β-estradiol via
granulosa cells in the mouse.
VEGFA suppresses apoptosis in vascular endothelial cells by regulating Bcl-2
family proteins (Gerber et al., 1998; Nör et al., 1999). The members of this family consist
of anti-apoptotic factors (such as Bcl-2 and Bcl-xL) and pro-apoptotic factors (such as
Bax). Bcl-2 maintains permeability of the mitochondrial membrane. However, Bax
increases permeability of the mitochondrial membrane and stimulates apoptosis inducers
(such as cytochrome C and Smac/Diablo) which were released from mitochondria into
the cytosol. The mitochondrial apoptotic inducers in the cytosol stimulate the activation
of the caspase cascade. Activated caspase cascades can result in apoptosis. VEGFA is a
key survival factor for endothelial cells and induces the expression of Bcl-2 in human
endothelial cell (Gerber et al., 1998). Local inhibition of VEGFA activity appeared to
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produce an increase in ovarian apoptosis through an imbalance among the follicular
contents of Bcl-2 family members’ protein, thus leading a larger number of atretic
follicles (Abramovich et al., 2006).
However, VEGFA does not stimulate or inhibit Bcl-xL and Bax, respectively, in
bovine Granulosa cells. It is hypothesized that VEGFA does not suppress the expression
of active caspase-3. VEGFA suppresses granulosa cell apoptosis by suppressing the
downstream activities of caspase-3 without being associated with the mitochondrial
pathway. Because VEGFA has tyrosine kinase receptors, it may act via Akt or Erk in the
downstream cascade of caspase-3 to inhibit granulosa cell apoptosis (Kosaka et al., 2007).
The exact mechanism of how VEGFA acts on the granulosa cell or follicular survival still
needs to be elucidated. Besides Bcl-2 and Bax, we also determined expression of other
genes in the ovary.
Foxo3a is a key oocyte factor critical for suppressing primordial follicle activation
(Castrillon et al., 2009). Foxo3a mRNA is 1.76 fold higher in KO’s ovary than control.
Although, the difference is not significant, the higher value in KO may suggest follicle
progression is suppressed in these ovaries. Gdf-9, produced by oocyte, plays critical roles
in early follicular development. This oocyte-derived paracrine factor also stimulates
follicular somatic cell proliferation and steroidogenesis (Elvin et al., 1999). There is no
statistical significant difference on Gdf-9 mRNA between the KO’s ovary and controls.
However, the mRNA average is 34% lower in VEGFA-DGranG ovary. Thus, less Gdf-9
expression may inhibit follicular development, somatic cell proliferation and estrogen
synthesis. We did not have enough tissue to evaluate protein for Bxl-2, Bax, Foxo3a, or
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Gdf-9. Thus it is also possible that difference in protein production of these genes result
from VEGFA isoform loss.
Our KO mice from the present study were subfertile. The time period from mating
to parturition in female VEGFA-DGranG mice was 12 days longer compared to the
control. This suggested a decreased rate of ovulation in the female VEGFA-DGranG
mice or ovulation of oocytes that are not competent to ovulate. Ha et al., suggest that
estrogen administration improves number and quality of oocytes which may possibly be
mediated by the increase of ovarian VEGF expression. In our study, reduced estrogen
may reduce the number and quality of oocytes and VEGFA expression in the ovary.
Furthermore, VEGFA loss in granulosa cells may diminish the number of healthy
preovulatory follicles and ovulated oocytes.
Follicular vascularization appears to have a critical influence on the development of
competing human oocytes and early embryos. Follicular vascularity and oxygen content
appear to be important factors of oocyte competence (Van. 1998). In an in vivo
experiment, Iijima et al. treated mature female rats with VEGFA120 or 164 and an
angiogenic inhibitor (TNP-470) during the estrous cycle. They reported that VEGFA
angiogenic treatment stimulated follicular angiogenesis, while TNP-470 treatment
showed severe depression of follicular angiogenesis and completely inhibited ovulation.
After treatment with VEGFA 120 and 164, the number of healthy preovulatory follicles
and ovulated oocytes significantly increased and the number of atretic preovulatory
follicles decreased (Iijima et al., 2005). In Iijima’s experiment, the oocytes ovulated had
a normal ability to fertilize and develop to term with the same litter size as in the control
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rats. In the current study, to determine the quality of the oocytes ovulated by granulosa
cell-specific VEGFA loss, VEGFA-DGranG mice were mated with VEGFA-DSertG
mice and allowed to proceed to pregnancy. The number of litters/female in approximate
two months or pups/litter was not significantly different between the VEGFA-specific
knockout mice and controls. However the time to produce a litter was longer in our
knockout matings suggesting that there may be multiple problems in obtaining viable
embryos that are capable of being maintained for a complete pregnancy. Thus, granulosa
cell-specific VEGFA loss may have effects on embryo viability.
In conclusion, we demonstrated that removal of VEGFA in granulosa cells within
ovaries resulted in reduced ovarian weight, fewer CL and reduced estrogen
concentrations (by 55%). Furthermore, the time period between mating and parturition is
longer in female VEGFA-DGranG KO’s than that in controls. The present data suggest
that VEGFA is necessary for normal follicular development, ovulation rate, estrogen
concentration and timing of mating to parturition and without VEGFA angiogenic and
antiangiogenic isoforms females are subfertile.
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Figure Legends
Table 1. Quantitative Real-time PCR primers, probes and kit.
Figure 1. Effect of granulosa cell-specific VEGFA loss on morphology of ovary.
Histological images of sections (H&E stained) of control ovaries (A, C, E) and VEGFADGranG ovaries (B, D, F, G). Two VEGFA-DGran ovaries had abnormal morphology in
structures that appeared to be CL (F, G).
Figure 2. Effect of granulosa cell-specific VEGFA loss on ovaries (A) uterus (B),
kidneys (C) and adrenals (D) in female mouse. The mean weights + SEM are presented. *
denotes significant difference at P < 0.05.
Figure 3. Cyp11a1 immunohistochemistry (IHC) images (A, B, C) and effect of
granulosa cell-specific VEGFA loss on the numbers of Corpus Lutea (D). A is showing
the H&E stained CL, B is showing Cyp11a1 IHC stained CL (brown color), and C is the
negative control for IHC. The mean numbers of CL per ovary + SEM are presented. *
denotes significant difference at P < 0.05.
Figure 4. Effect of granulosa cell-specific VEGFA loss on the serum E2 (A),
progesterone (B) and testosterone (C) concentrations. The mean serum concentrations +
SEM are presented. * denotes significant difference at P < 0.05.
Figure 5. Effect of granulosa cell-specific VEGFA loss on Bcl-2 (A), Bax (B), Bcl-2/Bax
(C), Foxo3a (D), Gdf-9 (E), Cyp17a1 (F) and Cyp11a1 (G) mRNA expression in the
ovary. The mean normalized values + SEM are presented.
Figure 6. Time from mating control female with control male to parturition VS time
from mating VEGFA-DGranG females with VEGFA-DSertG males to parturition. There
were 5 KO groups and 9 control groups. The mean days from mating to parturition +
SEM are presented. * denotes significant difference at P < 0.05.
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Gene

Forward Primer

Gapdh

Probe

Probe

Dye

Vendor

Reverse Primer

Kit-Taqman Rodent GapDH Control Reagents Applied Biosystems Catalog #4308313
(VIC Probe)

Bcl-2

CGTTGGCCCTTCGGAGTT

FAM

Applied

TCAGACCTCCAGGGCAGAGA

Biosystems

Bax

GGCCTTTTTGCTACAGGGT

FAM

Gdf-9

Cyp17a1

Cyp11a1

GTGTCTCCCCAGCCATCCT

Biosystems

TT
Foxo3a

Applied

GCAAAGCAGACCCTCAAA

SYBR

Applied

CTG

Green

Biosystems

GCCGGGCAAGTACAGCC

SYBR

Applied

Green

Biosystems

TGGAAGGATGCACAGGTT

SYBR

Applied

GA

Green

Biosystems

CCCCCTGGGTGGCCTAT

SYBR

Applied

TGAACTCTTAAACAGGACCCCA

Green

Biosystems

AT

Table 1.

TGAGAGCAGATTTGGCAAAGG

TTTGTAAGCGATGGAGCCG

ATGGGATCCGGGACGTTAG
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Figure 1.
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Chapter 3
Sertoli cell-specific Vascular Endothelial Growth Factor A (VEGFA) loss using
pDMRT-1 Cre reduces testis size, increases testosterone, and affects genes involved in
the apoptotic pathway resulting in subfertile males
Abstract:
VEGFA is present during testis morphogenesis and is expressed by Sertoli cells and
germ cells. Inhibition of VEGFA disrupts both testis-specific vascular development and
cord formation. We hypothesize that production of VEGFA isoforms by Sertoli cells is
critical for normal testis morphogenesis. Therefore, the objective of the current study was
to evaluate the effects of Sertoli cell-specific production of VEGFA isoforms on sexspecific vascular development and gonadal morphogenesis. The pDmrt1 gene is
expressed in the indifferent gonad in precursor Sertoli and granulosa cells and in some
sub-populations of germ cells. Therefore, we used a pDMRT1-cre crossed to a floxed
VEGFA mouse to generate male Sertoli-cell (VEGFA-DSertG) specific knockouts.
Reproductive organs were collected from adult mice, and weighed (control n=9, VEGFADSertG n=8). Testosterone concentrations in blood were determined by ELISA. In
VEGFA-DSertG males, the body weight (28.52+0.48 VS 32.52+1.20 g); testes
(0.1658+0.0064

VS

0.1924+0.0061

g)

and

epididymal

(0.0627+0.0046

VS

0.0792+0.0042 g) weight were significantly reduced compared to controls (P < 0.05).
The prostate weight in VEGFA-DSertG males also tended to be smaller than controls
(0.0104+0.0031 VS 0.0215+0.0044 g, P = 0.06). Morphologically the epididymis and
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prostate were different with fewer tubules and sperm in the epididymis and reduced
branching in the prostate compared to controls. Serum testosterone levels in VEGFADSertG males tended to be higher than those in controls (5.28+2.24 VS 0.97+0.33 ng/ml,
P = 0.097). Three VEGFA-DSertG males had 10 fold greater testosterone concentrations
than controls (12.81 VS 0.97 ng/ml). Relative amounts of Bcl-2 mRNA in VEGFADSertG testes tended to be greater than that in controls (4.51+1.26 VS 1.89+0.27, P =
0.07). The ratio of Bcl-2/Bax tended to be increased in VEGFA-DSertG testes compared
to control (1.20+0.33 VS 0.54+0.08, P = 0.08). Relative amounts of Bax (3.71+0.52 VS
4.10+0.53, P = 0.67), Sin3a (34.17+9.97 VS 18.72+2.90, P = 0.17) and aromatase
(10.77+2.3 VS 9.01+1.77, P = 0.56) mRNA in VEGFA-DSertG testes were not
significantly different compared to control. But Sin3a mRNA in three VEGFA-DSertG
males with high testosterone concentration was significantly higher than controls
(42.08+13.91 VS 18.72+2.90, P = 0.01). Therefore, we can conclude from these data that
lack of VEGFA in Sertoli cells (and sub-populations of germ cells) reduces gonadal and
male accessory gland organ weights, alters steroidogenic profiles and Bcl-2 and Sin3a
expression in testis. Thus, VEGFA plays an important role in male reproductive organ
morphogenesis and function in mice.
Introduction
Human fertility rates have declined all over the world. Currently, increased human
infertility suggests that significant reproductive health problems exist (Skakkebaek et al.,
2005) and this is why they have identified a new disorder- testicular dysgenesis syndrome
(TDS). Male reproductive health disorders, including impaired semen quality, testicular
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cancer, cryptorchidism and hypospadias are all associated with testicular dysgenesis
syndrome which is thought to occur due to abnormal embryonic or fetal development of
cells involved in testis differentiation and morphogenesis (Joensen et al., 2009).
Testis development is initiated by Sertoli cell differentiation and expression of Sry,
causing mesonephric cell migration into the differentiating testis to form seminiferous
cords (Cupp and Skinner 2005). Seminiferous cord formation and sex-specific vascular
formation are only present in the testis and therefore are first to distinguish morphology
in the indifferent gonad. Vascular endothelial growth factor A (VEGFA) is a paracrine
growth factor responsible for blood vessel development as well as endothelial cell
migration. Expression of VEGFA in normal testes, prostate and seminal vesicles and
semen suggests that VEGFA could play a role in male reproductive physiology
(Huminiecki et al., 2001; Obermair et al., 1999).
The Vegf family includes Vegfa, Vegfb, Vegfc, Vegfd (officially called Figf, c-fosinduced growth factor) and placenta growth factor (Pgf). The predominant gene in Vegf
family is Vegfa. The Vegfa gene is composed of eight exons and by different factors
produces angiogenic or inhibitory isoforms. These two isoforms have opposite functions
(angiogenic isoforms promote vasculature development while anti-angiogenic isoforms
inhibit vascular development). Two related tyrosine kinases receptors, FMS-like tyrosine
kinase 1(FLT1, also known as VEGFR1) and kinase insertion domain receptor (KDR,
also known as VEGFR2 and FLK-1), bind to VEGFA. The primary receptor involved in
the action of VEGFA is KDR (Ferrara et al., 2003). KDR is the major mediator of the
mitogenic, angiogenic and permeability effects of VEGFA. It has been demonstrated that
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KDR participate in mediating endothelial cell proliferation, survival and vascular
permeability, whereas FLT1 might play an inhibitory role by sequestering VEGFA, and
preventing its interaction with KDR (Ferrara et al., 2004).
VEGFA and its receptor KDR are detected at the time of testis morphogenesis.
VEGFA is expressed by Sertoli cells and other cells within the seminiferous cords in
early development (Bott et al., 2006). FLT1 and KDR were expressed by both Leydig
cells and germ cell of the testis (Korpelainen et al., 1998; Bott et al., 2006; Bott et al.,
2010). It has been demonstrated that overexpression of VEGFA in the testis and
epididymis of transgenic mice leads to upregulation of VEGFA receptors in the
endothelial cells, in certain spermatogenic cells and the Leydig cells, and causes
infertility. The VEGFA overexpression in testis and epididymis exhibited spermatogenic
arrest and the ductus epididymidis was dilated, containing areas of epithelial hyperplasia
in mice (Korpelainen et al., 1998). In the previous studies, our laboratory demonstrated
that VEGFA, a Sertoli cell secreted growth factor, is critical for both vascular
development and cord formation. Treatment with VEGFA antagonists or VEGFA
receptor signal transduction inhibitors arrested cord formation and reduced vascular
density in organ cultures of rat testes (Bott et al. 2006). Treatment of E13 cultured mouse
testes with VEGFA angiogenic isoform or an antibody to antiangiogenic isoforms (antiVEGFAxxxB) resulted in undefined and poorly developed seminiferous cords compared
with the cords in control. Moreover, the vasculature density increased in the cultured
mouse testes with VEGFA angiogenic isoform or an anti-VEGFAxxxB. The results
suggest that both pro- and antiangiogenic VEGFA isoforms are involved in the
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development of vasculature and seminiferous cords in rat testes, and differential
expression of these isoforms may be important for normal gonadal development (BaltesBreitwisch et al., 2010). Recently, we also found that KDR-LacZ testis cultured with
VEGF receptor tyrosine kinase inhibitor (VEGFR-TKI) present reduced endothelial cell
migration during testis development (Bott et al., 2010). Taken together, these studies
suggest that VEGFA, secreted by Sertoli cells, is involved in the development of
vasculature and seminiferous cords in rodent testes.
We proposed that VEGFA plays an important role in testis morphogenesis and
function. To investigate the effects of VEGFA in vivo, we generated Sertoli cell-specific
VEGFA loss transgenic mice. The objective of present study is to determine the in vivo
effects of Sertoli cell-specific VEGFA loss on male reproductive organs’ function and
morphogenesis.
Materials and methods
Animals:
Sertoli cell-specific VEGFA KO mice were obtained by using the Cre-loxP
approach. We used a line of VEGFAloxp/loxp mice (Gerber et al., 1999) from Napoleon
Ferrara at Genentech to mate with pig DMRT1-cre mice (Boyer et al., 2002) to develop
Sertoli and granulosa cell-specific VEGFA knockout mice (breeding scheme in Appendix
A). The Dmrt1 gene is expressed in the indifferent mouse gonad at 10.5 dpc in precursor
cells that differentiate into Sertoli and granulosa cells. By 12.5 dpc, Dmrt1 is expressed in
Sertoli cells and germ cells within XY gonads and in ovarian somatic cells and germ cells.
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DMRT1 is presented in Sertoli cells at all ages examined and absent in ovarian somatic
cells from 13.5 dpc. Expression of Dmrt1 in primordial germ cells increases through 13.5
dpc and is absent by 15.5 dpc. In germ cell, DMRT1 was detected only in spermatogonia
of the testis after birth (Lei et al., 2007). The pDmrt1 gene is expressed similar to mouse
Dmrt1 (Boyer et al., 2002). In our VEGFA-DSertG mouse, VEGFA gene exon 3 was
flanked by two loxp and Cre, driven by pig Dmrt1, bound and deleted the DNA sequence
between the two loxp. The VEGFA was not expressed in the cells where Dmrt1 is present.
Therefore, we expected potential phenotypes in male Sertoli and female granulosa cell
(and sub-populations of germ cell) knockouts. We used Cre-negative VEGFAloxp/loxp or
VEGFAloxp/+ mice as controls and Cre-positive VEGFAloxp/loxp mice as KO (VEGFADSertG). Testes, epididymis, prostate, seminal vesicles, kidneys and adrenals were
collected from male adult mice (control n=9, VEGFA-DSertG n=8) and weighed. The
average age for the KO group was 178 days and for the control group was 175 days. All
animal protocols were approved by the University of Nebraska Institute of Animal Care
and Use Committee (IACUC) in accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals.
Genotyping:
DNA was extracted from tail samples and used for genotyping via polymerase chain
reaction (primers and PCR programs are listed in Appendix B). Genomic DNA was
extracted from tails of mice by proteinase K digestion and followed by 6M NaCl
extraction and ethanol precipitation (Bott et al., 2010).
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Embedding, Histology and staining (hemotoxylin and eosin staing; H&E):
Testes, epididymis and prostate were fixed in Bouin’s solution and rinsed in 70%
ethanol. Embedding was performed according to standard procedures (McFee et al., 2009;
Bott et al., 2010). Prior to paraffin embedding, tissues were rinsed in 100% ethanol 1
hour for 3 times and CitriSolve (Fisher Scientific, Fairlawn, IL) 1 hour for 3 times.
Embedded tissues were sectioned (5 µm) and the slides were placed in an incubator
(37 °C) overnight. Sectioned tissues were deparaffinized, stained with hematoxylin for 1
min (VWR International, West Chester, PA) and eosin for 30 min (Ricca, Arlington, TX),
dehydrated and mounted.
Immunohistochemistry:
Sectioned tissues were deparaffinized, rehydrated, and microwaved in 0.01 M
sodium citrate to boil for 15 min. Then, tissues were cooled for 1 h and rinsed in 3%
hydrogen peroxide in methanol for 20 min. Sections were blocked with 10% normal goat
serum in PBS for 30 min at room temperature and washed in PBS 3 times.
Immunohistochemistry was performed according to the standard protocol in our
laboratory (Mcfee et al., 2009). DDX4/MVH, a primordial germ cell marker, (catalog
number: ab13840; Abcam, Cambridge, Mass., USA) was diluted 1:500 in 10% normal
goat serum. The aromatase primary antibody (catalog number: ab18995; Abcam) was
diluted in 1:100 in 10% normal goat serum. As a negative control, serial sections were
processed without primary antibody. Biotinylated goat anti-rabbit secondary antibodies
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were diluted 1:300. Secondary antibody was detected using aminoethyl carbazole (AEC)
chromagen substrate solution (ZYMED Laboratories, San Francisco, CA).
RNA isolation:
Total RNA from testes was extracted using Tri-Reagent according to manufacturer’s
protocol (Sigma, St. Louis, MO). After isolation total RNA was dissolved in 20 µl diethyl
pyrocarbonate (DEPC) water. The extracted RNA was diluted 1:14 in DEPC water and
the concentration was determined by spectroscopy at 260nm using the Lambda EZ 150
(Perkin Elmer).
Reverse Transcription (RT)-PCR:
Before RT-PCR, 1 µl of RNA was removed from each sample to a new tube with 15
µl DEPC water to be used as ―No RT‖ to detect the residual genomic DNA. RT was
performed on 5 µg of template using SuperScript II (Invitrogen, Carlsbad, CA) according
to the manufacturer’s recommended protocol (McFee et al., 2009; Bott et al., 2010). RT
samples were incubated in 65°C with 2 µl of oligo (dT) 15 primer (Promega), 2 µl
dexoxynucleotide triphosphates (Fermantas; 10 mM dNTP mix), 3.8 µl DEPC water, and
then immediately chilled on ice. After that, 1 µl SuperScript II reverse transcriptase (200
units/ µl; Invitrogen, Carlsbad, CA), 3.2 µl of stand buffer (Invitrogen, Carlsbad, CA), 2
µl 0.1 M DL-dithiothreitol (DTT) (Invitrogen, Carlsbad, CA), 1 µl DEPC water were
added into each sample. The samples were incubated at 42°C for 1 hour followed by 15
mins at 70°C to inactivate the reverse transcriptase. The cDNA was stored at 20°C for
subsequent real time-PCR.
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Quantitative RT- PCR (QRT-PCR):
Primers, probes and kit used in the experiment were shown in table 1.
Glyceradehyde-3-phosphate dehydrogenase (Gapdh) gene is a housekeeping gene and
used as a control for RNA amplification. QRT-PCR was performed in 364 well plates
(Axygen Scientific, Union City, CA) with an adhesive cover film (VWR, Scientific
Products, North Kansas City, MO). Bcl-2, Bax and Aromatase were performed with 10 µl
Taqman universal Master Mix (Applied Biosystem, Foster City, CA), 1 µl cDNA, 0.5 µl
of each forward and reverse primers, 2 µl probe, and 6 µl DEPC to make up the reaction
volume to 20 µl. Sin3a were performed with 10 µl Taqman universal Master Mix
(Applied Biosystem, Foster City, CA), 1 µl cDNA, 1 µl of primers and probe mix
(Applied Biosystem, Foster City, CA), and 8 µl DEPC to make up the reaction volume to
20 µl. Experimental and Gapdh PCRs were carried out in separate wells in triplicate. An
arbitrary value of template was assigned to the highest standard and corresponding values
were assigned to the subsequent dilutions. These relative values are plotted against the
threshold value for each dilution to generate a standard curve. The relative amount for
each experimental and Gapdh triplicate was assigned an arbitrary value based on the
slope and y-intercept of the standard curve. The average of the experimental triplicate is
divided by the average of the Gapdh triplicate, and the resulting normalized values are
used for statistical analysis (McFee et al. 2009).
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Blood collection and Hormone Enzyme-Linked Immunosorbent Assay (ELISA):
Blood was collected at the time of euthanization and put into tubes with 20 µl EDTA
solution (Fisher Scientific Co., Fair Lawn, NJ). Blood sample was immediately
centrifuged at 1250 X g for 10 min; the plasma was removed into a new tube and stored
in -80°C. Testosterone concentration was determined by Testosterone ELISA kit (Alpha
Diagnostics International Inc., San Antonio, TX; Cat. No.1880). Standard curve samples
were made of 0 ng/ml, 0.5 ng/ml, 1 ng/ml, 2.5 ng/ml, 10 ng/ml and 20 ng/ml. Assay
sensitivity was 0.125 ng/ml.
Statistical analysis:
All data were analyzed by two-sample t-test using SAS software (SAS institute,
Cary, NC). Differences in data were considered statistically significant at P < 0.05
Results
Phenotypes in the male testis of VEGFA-DSertG mice:
In VEGFA-DSertG, the body and testes weights were significantly smaller than
those from the control (body: 28.52+0.48 VS 32.52+1.20 g; testes: 0.1658+0.0064 VS
0.1924+0.0061 g, P < 0.05; fig. 1G and 1H). To assess the effect of Sertoli cell-specific
VEGFA loss on testes histological morphology, testes were stained with H&E. There was
no significant difference in morphology of testis (fig. 1A-F).
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Phenotype of seminal vesicles, kidneys and adrenals in VEGFA-DSertG:
In VEGFA-DSertG, seminal vesicles, kidneys and adrenals weight were not
significantly different compared to those in control (seminal vesicles: 0.2324+0.0134 VS
0.2579+0.0281 g, P = 0.43; kidneys: 0.4673+0.0122 VS 0.4947+0.0239 g, P = 0.34;
adrenals: 0.0077+0.0022 VS 0.0068+0.0016 g, P = 0.7).
Gene expression in testis:
Because it is demonstrated that VEGFA angiogenic isoform treatment increased the
expression of Bcl-2 relative to Bax in bovine testis (Caires et al., 2009). We evaluated
Bcl-2 and Bax mRNA expression in the testis. As shown in fig. 2A, Bcl-2 in VEGFADSertG tended to be higher than that in control (4.51+1.26 VS 1.89+0.27, P = 0.07).
Sertoli cell-specific VEGFA loss stimulated production of Bcl-2 mRNA in testis. Bax in
VEGFA-DSertG was not different from controls (3.71+0.52 VS 4.10+0.53, P = 0.67, fig.
2B). In addition, Sertoli cell-specific VEGFA loss tended to increase the ratio of Bcl-2 to
Bax (1.20+0.33 VS 0.54+0.08, P = 0.08, fig. 2C). Swi-independent 3a (Sin3a) is
specifically expressed in Sertoli cells in the testis and it is required by Sertoli cells to
establish a niche for undifferentiated spermatogonia and spermatid elongation (Payne et
al., 2010). Relative amount of Sin3a mRNA was not significant different between
VEGFA-DSertG testes and control (fig. 2D) (34.17+9.97 VS 18.72+2.90, P = 0.17).
However, the amount of Sin3a mRNA in those three male KOs with high testosterone
was significantly higher than the controls (42.08+13.91 VS 18.72+2.90, P = 0.01, fig.2E).
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Effect of Sertoli cell-specific (and sub-populations of germ cell) VEGFA loss on
testosterone concentration in serum and aromatase in testis:
Blood was collected to test circulating hormone levels. Serum testosterone
concentration in the VEGFA-DSertG mice tended to be higher than those in control mice
(5.28+2.24 VS 0.97+0.33 ng/ml, P = 0.097, fig. 3G). The testosterone concentrations in
three VEGFA-DSertG mice had 10 fold (13.83, 13.72, 10.88 ng/ml) higher
concentrations compared to controls (0.97+0.33 ng/ml, fig. 3H). Aromatase converts
testosterone

to

estrogen

in

Sertoli

cells.

We

stained

for

aromatase

with

immunohistochemistry. It is shown that aromatase was expressed in both Leydig cells,
some germ cells and Sertoli cells. Aromatase positive staining in VEGFA-DSertG was
not significantly different from that in the control (fig 3A-F). Aromatase mRNA
(10.77+2.3 VS 9.01+1.77, P = 0.56, fig. 3I) in testis was not significantly different
between VEGFA-DSertG and controls.
Effect of Sertoli cell-specific (sub-populations of germ cells) VEGFA loss on germ cell:
To examine whether Sertoli cell-specific VEGFA loss alter the germ cell numbers in
testis, we used immunohistochemistry for VASA (a known germ cell marker) to
determine if there were differences in germ cell numbers. There was no difference in the
germ cell number on randomly counted areas of the testis between the VEGFA-DSertG
and control (fig. 4) as measured with VASA positive staining.
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Effect of Sertoli cell-specific VEGFA loss on epididymis:
Epididymis is part of reproductive tract in the male, which was also observed in the
current study. Epididymal weight in VEGFA-DSertG was significantly smaller than that
in control (0.0627+0.0046 VS 0.0792+0.0042 g, P < 0.05, fig. 5G). To evaluate the
morphology, the epididymis was embedded, sectioned and stained with hematoxylin and
eosin (H&E). The epididymal head in VEGFA-DSertG appeared to have fewer tubules
than the control. Besides the reduced numbers of tubules, VEGFA-DSertG epididymis
also appeared to have fewer sperm in lumen than the controls (fig. 5A-F).
Effect of Sertoli cell-specific VEGFA loss on prostate:
The prostate is an important gland in males. The prostate gland produces, and
secretes an alkaline fluid which is a part of semen and provides a protective buffer for
sperm survival in the oviduct. In the present study, the prostate in VEGFA-DSertG males
also tended to be smaller than controls (0.0104+0.0031 VS 0.0215+0.0044 g, P = 0.06,
fig. 6G). The VEGFA-DSertG prostate showed less branching and a less differentiated
morphology than the control (fig. 6A-F).
Effect of Sertoli cell-specific (sub-populations of germ cells) VEGFA loss on fertility:
To determine whether Sertoli cell-specific VEGFA loss has any effect on fertility,
VEGFA-DSertG mice were mated with females that had VEGFA knocked out in
granulosa and some germ cells (VEGFA-DGranG). There were 5 KO groups and 9
control groups. We found that the number of days for VEGFA-DGranG females mating
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with VEGFA-DSertG males until parturition was longer than that for control females
mating with control males (38.27+4.65 VS 26.18+2.17 days, P < 0.05, fig. 7).
Discussion:
In the present study, we used Cre-lox technology to knockout VEGFA in Sertoli
cells and in sub-populations of germ cells. Our goal was to determine how this affected
morphology and function. We demonstrated that removal of VEGFA in VEGFA-DSertG
males affected growth since body weight, testis and epididymal weights were smaller
with tendencies for the prostate to be smaller. Furthermore, Bcl-2 mRNA expression also
increased in VEGFA-DSertG testis, suggesting that increased cell apoptosis may occur.
Furthermore, the Sertoli cell-specific VEGFA loss affected the morphology of
epididymis and prostate resulting in fewer tubules in the epididymis and reduced
branching in the prostate.
VEGFA is a key regulator of endothelial growth and permeability. However, an
increasing number of reports suggest that VEGFA has direct effects on nonvascular cells
including granulosa cells (Greenaway et al. 2004) and germ cells (Caires et al., 2009).
For transgenic mice, losing one of the VEGFA alleles also results in embryonic death
before testis development in utero (Ferrara et al. 1996). But the role of VEGFA in
extravascular cells has not yet been understood. We are the first to generate the Sertoli
cell-specific VEGFA loss mice. Because the VEGFA was conditional knockout, the
embryonic lethality did not occur. The adult mice were used to observe the effect of
VEGFA on testis morphology and function.
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Since previous studies in our laboratory demonstrated that rat testes treated with
inhibitors of VEGFA receptors and/or antagonists to VEGFA ligands during sex
differentiation had decreased vessel density (Bott et al., 2006); we initially proposed that
elimination of VEGFA in Sertoli cells may affect formation of the testis. This is
supported by other reports of VEGFA angiogenic isoform overexpression in testis also
increased capillary density in mice (Korpelainen et al., 1998). These data suggest that
VEGFA plays an important role in testis development. It may regulate the testis growth
through regulating vessel density and thus the smaller testis in VEGFA-DSertG may due
to less vessel density and inability of the testis to grow and develop due to inhibition of
proliferation and migration of necessary cells from the mesonephros. Our laboratory has
demonstrated that mesonephric cells expressing KDR appear to migrate into the
developing testis and surround developing seminiferous cords at E11.5 in the mouse.
Inhibition of VEGFA signal transduction impaired the migration of endothelial cells in
cultured gonad. Thus, VEGFA may regulate the endothelial cell migration in gonads
(Bott et al., 2010).
Secondly, we proposed that the reduced size of testis in the VEGFA-DSertG KO
mice was due to reduced total numbers of germ cells and developing sperm that were
present within the testis. There is supporting evidence that KDR is expressed in germ
cells during embryonic period and after birth in the testes suggesting that VEGFA may
affect differentiation and proliferation of spermatogonia (Bott et al., 2010). In bovine
testis, VEGFA164 treatment caused more germ cells (Caires et al., 2009). The VEGFA
overexpression in testis induced spermatogenic arrest and infertility in mice (Korpelainen
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et al., 1998). However, when we used VASA staining to determine germ cells numbers
there was no differences in VEGFA-DSertG males and controls on the randomly counted
areas of the testis. There does not appear to be any direct effect on germ cell numbers on
randomly counted areas of the testis. But the total number of germ cell may be altered, so
overall size of the testis was affected.
In the present study, the expression of Bcl-2 and Bcl-2/Bax were increased in
VEGFA-DSertG testis. One possibility is due to increased germ cell apoptosis signaling
that mice need more Bcl-2 to prevent the apoptosis. Recombinant mouse VEGFA_164
treatment increased numbers of germ cells in bovine testes following 5 days of culture
when compared with controls. Increased expression of Bcl-2 relative to Bax and
decreased expression of Bnip3 indicated VEGFA_164 also stimulated an intracellular
response that prevents germ cell death in bovine testis tissue explants. Blocking VEGFA
activity in vitro reduced the number of germ cells in VEGFA-treated testis tissue (Caires
et al., 2009). This suggests that VEGFA angiogenic isoform is a survival factor in germ
cell. Loss of all VEGFA isoforms may result in less germ cells developing and reduced
spermatogenesis. Increased germ cell apoptosis signaling may stimulate expression of
Bcl-2 to support germ cell survival and sperm production. Increased amount of Bcl-2 may
also be compensating for reduced VEGFA angiogenic isoforms. Besides, the higher Bcl-2
mRNA and Bcl-2/Bax in KOs, the Sin3a mRNA also increased in VEGFA-DSertG testes.
It is possible like Bcl-2, increased germ cell apoptosis or reduced sperm numbers
stimulate more Sin3a to support spermatogenesis.
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Testosterone concentration in plasma tended to be higher in VEGFA-DSertG mice
than controls because three VEGF-DSertG males had 10 fold greater testosterone
concentrations than controls (12.81 vs 0.97 ng/ml). One in vitro study showed that VEGF
angiogenic isoforms increased testosterone production in mouse TM3 Leydig cells by a
dose-dependent manner. Administration of anti-VEGF antibody to block the signaling
through VEGF receptor resulted in an inhibitory effect of testosterone secretion (Hwang
et al., 2007). However, an ectopic study showed no relationship between VEGF
angiogenic isoform treatment and serum testosterone concentration. In that study, bovine
testis

tissue

was

treated

with

VEGFA_164

before

grafting

onto

castrated

immunodeficient nude mice. Serum testosterone concentrations in mice with cultured
testis tissue grafts treated with VEGFA_164 were not different compared to mice
receiving control treatment (Schmidt et al., 2006). The role of VEGF in production of
testosterone is still unclear. In the current study, testosterone levels in three VEGFADSertG mice were 10 fold higher compared to controls. In VEGFA-DSertG mice, both
VEGF angiogenic and inhibitory isoforms were knocked out in Sertoli cells and some
germ cells. Loss of VEGF in Sertoli cells may affect the Leydig cell function and then
cause the increase in serum testosterone.
In testis, LH secreted from anterior pituitary through cAMP, stimulates synthesis
and release of testosterone by the Leydig cells. Aromatase converts testosterone to
estrogen. We did aromatase immunohistochemistry in the testis. Some studies reported
that estrogen is synthesis in Leydig cells and germ cell in the mouse (Wang et al., 2001;
Bilinska et al., 2003; Carreau et al., 2003; Hess and Carnes, 2004). In our studies,
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aromatase located in Leydig cells in the interstitial area, some germ cells and Sertoli cells.
VEGFA-DSertG testis aromatase did not present a difference compared to the controls.
QPCR showed that aromatase mRNA in VEGFA-DSertG testis was not different with
that in control. It is possible since we were only knocking out VEGFA in Sertoli cells that
we were unable to detect differences in genes that are not specific to Sertoli cells. The
result indicated that in VEGFA-DSertG mice, the VEGFA loss influenced the
testosterone production via other enzyme or pathways potentially not through aromatase.
Body growth and male accessory gland organ development are affected by the
testosterone. The increase in testosterone synthesis in male body after birth leads to a
male pattern of growth hormone secretion and affects body growth. The testosterone
level might be deficient at certain stages during development in VEGFA-DSertG mice.
Thus, deficient testosterone may cause the lower weight of the body, testes and
epididymis in VEGFA-DSertG mice. The VEGFA-DSertG prostate weight also tended to
be smaller.
The epididymis is derived from the Wolffian duct and consists mainly of
mesenchymal tissue at birth (Cornwall, 2009). Androgens are important for normal
epididymal morphology and function while LH could be required for certain facets of
epididymal morphology and function (Lei et al., 2003). In present study, the high
testosterone in VEGFA-DSertG could reduce the release of LH. Deficient LH may affect
the epididymal growth. Another possibility for smaller epididymis is that the testosterone
level might be deficient at stages during epididymal development.
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Besides androgens, the development of differentiated epithelium also requires the
influence of luminal factors from the testis (Rodriguez et al., 2002) which are poorly
understood. Ductus epididymidis was dilated in the VEGFA overexpressing transgenic
mice. The number of subepithelial capillaries in the epididymis was increased in
transgenic mice. This indicated that VEGFA is involved in the vessel development in
epididymis (Korpelainen et al., 1998). In current study, Sertoli cell-specific VEGFA loss
may affect epididymal growth through influencing vessel development and permeability
which could reduce epididymal size.
The prostate is an androgen target organ whose growth, morphology, and function
are dependent on the androgens produced by the testes. Five-α-dihydrotestosterone (DHT)
stimulates the development and growth of the prostate, but is not essential for prostatic
bud formation (Mahendroo et al., 2001). Androgens are required for prostatic
development through the androgen receptor (Wilson et al., 1995) and mesenchyme drives
prostatic epithelial development (Thomson et al., 2008). Regional differences in
branching morphogenesis and cytodifferentiation are controlled by the instructional
influences of mesenchyme and temporal expression of growth factors (Timms et al.,
2008). Sertoli cell-specific VEGFA loss may affect the size of prostate through DHT
which was not measured in the present study. Branching morphogenesis in VEGFADSertG was abnormal, suggesting prostate development may be altered by hormones or
reduced growth factors.
In the present study, the time period from mating to parturition in female VEGFADGranG X VEGFA-DSertG mice was longer compared to the control. This increase in
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time to pregnancy may be caused by problems with the reduction in female ovulation or
reduction in spermatogenesis or potentially reduced sperm cell viability due to less than
optimal seminal fluid quality. VEGFA-DSertG mice may lose expression of VEGFA in
some germ cells. VEGFA concentration in human semen is a factor that predicts
pregnancy success following IVF. Thus, too high or too low VEGFA in human semen is
also related to pregnancy failure (Huminiecki et al., 2001) and may contribute to the
longer time to conceive and have pups in our KO models.
Removal of VEGFA in Sertoli cells caused mice to be sub-fertile and resulted in
smaller body size, testis and epididymis. The serum testosterone level also tended to be
high in VEGFA-DSertG. In VEGFA-DSertG mice, the morphology of epididymis and
prostate was also altered. Sertoli cell-specific VEGFA loss also increased the Bcl-2 and
Sin3a expression in testis. Therefore, VEGFA plays an important role in male
reproductive organ morphogenesis and function for mice.
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Figure Legends
Table 1. Quantitative Real-time PCR primers, probes and kit.
Figure 1. Effect of Sertoli cell-specific VEGFA loss on the weights of male body (G) and
testes (H). Histological images of sections (H&E stained) of control testis (A, C, E) and
VEGFA-DSertG testis (B, D, F). The mean weights + SEM are presented. * denotes
significant difference at P < 0.05.
Figure 2. Expression of Bcl-2 (A), Bax (B) and the ratio of Bcl-2/Bax (C) and Sin3a (D)
mRNA in testis. Figure E is amount of Sin3a mRNA in VEGFA-DSertG males with high
testosterone. The mean normalized values + SEM are presented. ** denotes significant
difference at 0.05 < P < 0.1. * denotes significant difference at P < 0.05.
Figure 3. Effect of Sertoli cell-specific VEGFA loss on serum testosterone concentration
(G). Three VEGFA-DSertG males had 10 fold greater testosterone concentrations than
controls (H). Aromatase IHC in control testis (A, C) and VEGFA-DSertG testis (B, D).
Negative control in IHC for control testis (E) and VEGFA-DSertG testis (F). Expression
of Aromatase mRNA in the testis (I). The mean serum concentrations + SEM are
presented. The mean normalized values + SEM are presented. ** denotes significant
difference at 0.05 < P < 0.1.
Figure 4. VASA immunohistochemistry in testis. VASA (a known germ cell marker)
IHC in control testis (A, C) and VEGFA-DSertG testis (B, D). Negative control in IHC
for control testis (E) and VEGFA-DSertG testis (F).
Figure 5. Effect of Sertoli cell-specific VEGFA loss on weight of epididymis (G).
Histological images of sections (H&E stained) of control epididymis (A, C, E) and
VEGFA-DSertG epididymis (B, D, F). The mean weights + SEM are presented. *
denotes significant difference at P < 0.05.
Figure 6. Effect of Sertoli cell-specific VEGFA loss on weight of prostate (G).
Histological images of sections (H&E stained) of control prostate (A, C, E) and VEGFADSertG prostate (B, D, F). The mean weights + SEM are presented. ** denotes
significant difference at 0.05 < P < 0.1.
Figure 7. Time from mating control female with control male to parturition VS time
from mating VEGFA-DGranG females with VEGFA-DSertG males to parturition. There
were 5 KO groups and 9 control groups. The mean days from mating to parturition +
SEM are presented. * denotes significant difference at P < 0.05.
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Gene

Forward Primer

Gapdh

Probe

Probe

Dye

Vendor

Reverse Primer

Kit-Taqman Rodent GapDH Control Reagents Applied Biosystems Catalog #4308313
(VIC Probe)

Bcl-2

CGTTGGCCCTTCGGAGT

FAM

GGCCTTTTTGCTACAGG

FAM

Aromatase

GTGTCTCCCCAGCCATCCT

Kit-Taqman Gene Expression Assay Mm00488255_m1 (FAM Probe)
AACCCGAGCCTTTGGAG
A

Table 1.

Applied
Biosystems

GTTT
Sin3a

TCAGACCTCCAGGGCAGAGA

Biosystems

T
Bax

Applied

FAM

Applied
Biosystems

GGCCCGTCAGAGCTTTCA

92

G

Figure 1.

H

93

A

D

B

E
60
Control

*
Sin3a/Gapdh
(arbitary units)

50
40
30
20
10
0

C

Figure 2.

VEGFA-DSertG
with high T

*

94

H
Serum T concentration
(ng/ml)

G
**

8
7
6
5
4
3
2
1
0
Control

I

Figure 3.

VEGFA-DSertG

95

Figure 4.

96

G

Figure 5.

97

G

Figure 6.

98

Figure 7.

99

Literature Cited
Baltes-Breitwisch MM, Artac RA, Bott RC, McFee RM, Kerl JG, Clopton DT, Cupp AS.
Neutralization of vascular endothelial growth factor antiangiogenic isoforms or
administration of proangiogenic isoforms stimulates vascular development in the rat
testis. Reproduction. 2010. 140:319-329.
Bilinska B, Kotula-Balak M, Gancarczyk M, Sadowska J, Tabarowski Z, Wojtusiak A.
Androgen aromatization in cryptorchid mouse testis. Acta Histochem. 2003.105:5765.
Bott RC, McFee RM, Clopton DT, Toombs C, Cupp AS. Vascular endothelial growth
factor and kinase domain region receptor are involved in both seminiferous cord
formation and vascular development during testis morphogenesis in the rat. Biol
Reprod. 2006. 75:56-67.
Bott RC, Clopton DT, Fuller AM, McFee RM, Lu N, McFee RM, Cupp AS. KDR-LacZexpressing cells are involved in ovarian and testis-specific vascular development,
suggesting a role for VEGFA in the regulation of this vasculature. Cell Tissue Res.
2010. 342:117–130.
Boyer A, Dornan S, Daneau I, Lussier J, Silversides DW. Conservation of the
function of DMRT1 regulatory sequences in mammalian sex differentiation. Genesis.
2002. 34:236-243.
Caires KC, de Avila J, McLean DJ. Vascular endothelial growth factor regulates germ
cell survival during establishment of spermatogenesis in the bovine testis.
Reproduction. 2009. 138:667-677.
Carreau S, Lambard S, Delalande C, Denis-Galeraud I, Bilinska B, Bourguiba S.
Aromatase expression and role of estrogens in male gonad : a review. Reprod Biol
Endocrinol. 2003. 1:35.
Cornwall GA. New insights into epididymal biology and function. Hum Reprod Update.
2009. 15:213-527.
Cupp A, Skinner M. Embryonic Sertoli Cell Differentiation. In: Griswold M, Skinner M
(eds.), Sertoli Cell Biology, vol. 1. San Diego: Elsevier Academic Press; 2005. 43-70.
Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L,
Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted
inactivation of the VEGF gene. Nature. 1996. 380:439-442.
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med.
2003. 9:669-676.
Ferrara N. Vascular endothelial growth factor: basic science and clinical progress.
Endocrine Reviews. 2004. 25:581-611.
Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD,
Radtke F, Aguet M, Ferrara N. VEGF is required for growth and survival in
neonatal mice. Development. 1999. 126:1149-1159.
Greenaway J, Connor K, Pedersen HG, Coomber BL, LaMarre J & Petrik J 2004
Vascular endothelial growth factor and its receptor, Flk-1/KDR, are cytoprotective in
the extravascular compartment of the ovarian follicle. Endocrinology. 145:2896–2905.

100

Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev
Cancer. 2008. 8:880-887.
Hess R.A., Carnes K. The role of estrogen in testis and the male reproductive tract: a
review and species comparison. Anim. Reprod. 2004. 1:5-30.
Huminiecki L, Chan HY, Lui S, Poulsom R, Stamp G, Harris AL, Bicknell R. Vascular
endothelial growth factor transgenic mice exhibit reduced male fertility and placental
rejection. Mol Hum Reprod. 2001. 7:255-264.
Hwang GS, Wang SW, Tseng WM, Yu CH, Wang PS. Effect of hypoxia on the release
of vascular endothelial growth factor and testosterone in mouse TM3 Leydig cells.
Am J Physiol Endocrinol Metab. 2007. 292:E1763-E1769.
Joensen UN, Skakkebaek NE, Jørgensen N. Is there a problem with male reproduction?
Nat Clin Pract Endocrinol Metab. 2009. 5:144-145.
Korpelainen EI, Karkkainen MJ, Tenhunen A, Lakso M, Rauvala H, Vierula M,
Parvinen M, Alitalo K. Overexpression of VEGF in testis and epididymis causes
infertility in transgenic mice: evidence for nonendothelial targets for VEGF. J Cell
Biol. 1998. 143:1705-1712.
Lei N, Hornbaker KI, Rice DA, Karpova T, Agbor VA, Heckert LL. Sex-specific
differences in mouse DMRT1 expression are both cell type- and stage-dependent
during gonad development. Biol Reprod. 2007. 77:466-475.
Lei ZM, Zou W, Mishra S, Li X, Rao ChV. Epididymal phenotype in luteinizing
hormone receptor knockout animals and its response to testosterone replacement
therapy. Biol Reprod. 2003. 68:888-895.
Mahendroo, M.S., Cala, K.M., Hess, D.L. and Russell, D.W. (2001) Unexpected
virilization in male mice lacking steroid 5 alpha-reductase enzymes. Endocrinology.
142:4652–4662.
McFee RM, Artac RA, McFee RM, Clopton DT, Smith RA, Rozell TG, Cupp AS.
Inhibition of vascular endothelial growth factor receptor signal transduction blocks
follicle progression but does not necessarily disrupt vascular development in perinatal
rat ovaries. Biol Reprod. 2009. 81:966-977.
Obermair A, Obruca A, Pöhl M, Kaider A, Vales A, Leodolter S, Wojta J, Feichtinger W.
Vascular endothelial growth factor and its receptors in male fertility. Fertil Steril.
1999. 72:269-275.
Payne CJ, Gallagher SJ, Foreman O, Dannenberg JH, Depinho RA, Braun RE. Sin3a is
required by sertoli cells to establish a niche for undifferentiated spermatogonia, germ
cell tumors, and spermatid elongation. Stem Cells. 2010. 28:1424-1434.
Rodriguez CM, Kirby JL, Hinton BT. The development of the epididymis. In: Robaire B,
Hinton BT (eds). The Epididymis: From Molecules to Clinical Practice. New York:
Kluwer Academic/Plenum Publishers. 2002. 251–267.
Schmidt JA, de Avila JM, McLean DJ. Effect of vascular endothelial growth factor and
testis tissue culture on spermatogenesis in bovine ectopic testis tissue xenografts. Biol
Reprod. 2006. 75:167-175.
Skakkebaek NE, Jørgensen N. Testicular dysgenesis and fertility. Andrologia. 2005.
37:217-218.

101

Timms BG. Prostate development: a historical perspective. Differentiation. 2008. 76:565577.
Thomson AA, Cunha GR, Marker PC. Prostate development and pathogenesis.
Differentiation. 2008. 76:559-564.
Wang ZJ, Jeffs B, Ito M, Achermann JC, Yu RN, Hales DB, Jameson JL. Aromatase
(Cyp19) expression is up-regulated by targeted disruption of Dax1. Proc Natl Acad
Sci USA. 2001. 98:7988-7993.
Wilson, J.D., George, F.W. and Renfree, M.B. The endocrine role in mammalian sexual
differentiation. Recent Prog Horm Res. 1995. 50:349–364.

102

Appendix A: VEGFA Conditional Knockout Breeding Scheme
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Appendix B: Conventional PCR primers and programs for genotyping
Gene

Primer

Dmrt-1

Forward

5`-AGCAGAGGCTTCCTTCGACTT-3`

Reverse

5`-AGTGAACGAACCTGGTCGAAA-3`

Forward

5`-CCTGGCCCTCAAGTACACCTT-3`

VEGFA

lox/loxp

PCR program

VEGFA419

Reverse

5`- TCCGTACGACGCATTTCTAG-3`

VEGFA567

Sry

Forward

5`-CGGGATCCATGTCAAGCGCCCCATGA-3`

Reverse

5`- GCGGAATTCACTTTAGCCCTCCGATG-3`

1
2
3
4
5
6
7
1
2
3
4
5
6
7
8
1
2
3
4
5
6
7

94°C
94°
60°
72°
Go to 2
2°
4°
50°C
95°
95°
57°
72°
Go to 3
72°
4°
94°C
94°
58°
72°
Go to 2
72°
4°

4:00
1:00
0:15
0:15
30 times
5:00
forever
2:00
10:00
0:15
1:00
2:00
34 times
3:00
forever
1:00
1:00
1:00
1:00
29 times
5:00
forever
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Summary
In this thesis, we have demonstrated that the effects of Granulosa and Sertoli-cell
specific VEGFA loss on gonads, male accessory gland, organ function and
morphogenesis in vivo. We believe that the data in this thesis support our hypothesis that
VEGFA is critical for normal gonadal morphogenesis and function.
We utilized Cre-lox technology to knockout VEGFA in female Granulosa cells,
male Sertoli cells and sub-populations of germ in mice. We are the first to generate the
female Granulosa cell (VEGFA-DGranG), and male Sertolic cell-specific (VEGFADSertG) VEGFA loss mice. In our conditional knockout mice both VEGFA proangiogenic and anti-angiogenic isoforms were removed.
We have identified that removal of VEGFA in Granulosa cells within ovaries
resulted in smaller ovary, fewer CL, abnormal CL structure, and reduced 17beta-estradiol
concentrations in blood plasma. Removal of VEGFA in VEGFA-DSertG males affected
body weight, size of the testis, epididymis and prostate, as wells as increasing
testosterone concentrations (in three KO mice). In addition, Bcl-2 mRNA expression also
tended to be increased in VEGFA-DSertG testis when compared to controls and Sin3a
mRNA was increased in those three VEGFA-DSertG males with high serum testosterone
concentration than controls. Sertoli cell-specific VEGFA loss affected the morphology of
epididymis and prostate with fewer tubules in the epidiymus and reduced branching in
the prostate. The time period from mating to parturition in female VEGFA-DGranG X
male VEGFA-DSertG mice was longer compared to the control. This longer time to
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conception may be due to reduced ovulation of the VEGFA-DGranG female mice and /or
reduced quantity or quality of sperm in VEGFA-DSertG mice.
In summary, lack of VEGFA in Granulosa and Sertoli cells causes altered
reproductive gonadal morphogenesis, reduced gonadal and male accessory gland organ
weights, changed steroidogenic profiles and potentially caused subfertility in both male
and female mice.

